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Use of sedatives or 
tranquillisers and anti-
depressants in Ireland 
The National Advisory Committee on Drugs (NACD) 
recently published Bulletin 6 in the series of reports on the 
2010/11 general population survey on drug use in Ireland 
and Northern Ireland.1 The bulletin reports the prevalence 
of sedative or tranquilliser and anti-depressant use among 
adults aged 15–64 years. 
This article summarises, in separate sections, the 2010/11 
survey findings on sedative or tranquilliser use and on anti-
depressant use in terms of lifetime (ever), last-year (recent) 
and-last month (current) use, and compares them with 
the 2006/7 survey results. 
New Minister of State  
with responsibility for the 
National Drugs Strategy
Labour TD Mr Alex White succeeded  
Ms Róisín Shortall TD as Minister of State 
with responsibility for the National Drugs 
Strategy in September 2012.
In December Minister White announced  
the conclusions of a review of drugs task 
forces by the Department of Health.  
(See www.drugsandalcohol.ie/19054) 
The review recommends a series of reforms 
to better equip the task forces to respond to 
the current pattern of substance misuse.  
The key changes include:
 ■ Drugs task forces to be renamed ‘Drug 
and Alcohol Task Forces’;
 ■ A national co-ordinating committee to be 
established to guide the work of the task 
forces and drive implementation of the 
National Drugs Strategy;
 ■ Clearer terms of reference and corporate 
governance guidelines for the task forces;
 ■ Measures to encourage more public 
representative involvement in the work of 
the task forces; and 
 ■ Review of the number and boundaries of 
drugs task forces, mainly in Dublin.
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Sedatives or tranquillisers
‘Sedatives’ and ‘tranquillisers’ are commonly 
used terms for a group of medicines which 
depress brain and central nervous system 
activity.2 Benzodiazepines are the most common 
type of drug in this group; the 'Z-drugs', such 
as zolpidem and zopiclone, are also included in 
this group and have the same effect. Medically, 
sedatives or tranquillisers are often referred to as 
hypnotics (which treat insomnia) or anxiolytics 
(which relieve anxiety). The same drug can be 
used as a hypnotic or as an anti-anxiety agent 
depending on the dosage used and on the time 
of day that it is consumed. 
Key findings: sedatives or tranquillisers 
 ■ Prevalence rates were 14% for lifetime use, 
7% for last-year use and 3% for last-month 
use. There were statistically significant 
increases in the lifetime rate (up by 32%) 
and the last-year rate (up by 38%) since the 
last survey.
 ■ The prevalence rates for women were 
somewhat higher than those for men on all 
three measures: lifetime use (16% vs 12%), 
last-year use (7% vs 6%) and last-month use 
(3% vs 2%). 
 ■ The lifetime prevalence rate for men 
increased by 55% since the last survey, while 
the rate for women increased by 17%. The 
last-year prevalence rate for men increased 
by 54%, while the rate for women increased 
by 28%. Overall, the gap between men and 
women in terms of lifetime and last-year 
rates has narrowed.
 ■ Prevalence rates were higher among older 
adults (aged 35–64) than younger adults 
(aged 15–34) on all three measures: lifetime 
use (17% vs 10%), last-year use (8% vs 
5%) and last-month use (4% vs 1%). 
Lifetime and last-year rates increased in 
both age groups since the last survey, but 
the increases were substantially larger for 
the younger adult group. Lifetime rates for 
young adults increased by 71%, compared 
to 16% for older adults; last-year rates 
increased by 92%, compared to 20% for 
older adults. As a consequence, the gap 
between the older and younger age groups 
in terms of lifetime and last-year use has 
narrowed.
 ■ The median age at first use was 30 years, 
and was lower among men (28 years) than 
women (30 years). 
 ■ More than half (53%) of current users of 
sedatives or tranquillisers had taken them 
on 20 or more of the 30 days prior to the 
survey. Almost all (95%) said they had got 
the medicines on prescription from a doctor. 
 ■ Rates of use of sedatives or tranquillisers 
were highest at both ends of the social 
spectrum (among professionals and 
managers and among those who were 
dependent on long-term social assistance). 
 ■ Prevalence rates were higher among people 
who were separated, divorced or widowed 
than among married or co-habiting people. 
Discussion: sedatives or tranquillisers 
The misuse of certain prescribed medicines, 
including sedatives or tranquillisers, is of 
increasing concern in Europe,3 and is reported 
as a growing health problem globally.4 Such 
medicines can be more easily obtained than 
illicit drugs, and the potential for their misuse 
is widespread. In Ireland, these medicines 
are legally and appropriately prescribed to 
patients to treat medical conditions, including 
some mental health illnesses (such as anxiety, 
depression and other mood disorders). Their 
use for short periods of time is recommended 
to allow doctors or other health professionals 
and patients deal with or stabilise an underlying 
condition. 
The NACD survey is an important source of 
information to establish the extent and nature 
of use of these prescription medicines in the 
general population in Ireland and to identify 
which population groups are more likely to be 
prescribed such drugs. The 2010/11 NACD 
survey highlights several issues for attention.
The results show that the proportion of people 
using sedatives or tranquillisers has grown in 
recent years in Ireland. The reasons for this are 
not clear. Prevalence rates increased among 
the groups traditionally associated with these 
medicines (that is, women and the older 
population). However, the largest increases  
were in the rates of use by men and by  
young people. It is important to continue 
monitoring use of these drugs and to develop 
a better understanding of the patterns of use in 
sub-populations.5 
The survey also raises questions about the safety 
of the pattern of sedative or tranquilliser use 
in the general population. Clinical guidelines6,7 
recommend that, particularly with regard 
to anxiety-related conditions, many of these 
medicines should be prescribed for short-term 
(2–4 weeks) relief and taken for the shortest 
duration of time, with the least frequency 
possible, so as to avoid tolerance, drug 
dependence and the adverse effects of long-
term use. However, the survey shows that over 
half (53%) of all current users reported daily or 
almost daily use; the proportion rose to 63% in 
the older adult group. It is important to note 
that current users in Ireland are engaging in this 
frequency of use for periods of longer than one 
month and many may be at risk of experiencing 
a range of side effects, including dependence. 
Clinicians can play a critical role in identifying 
patients who may be at risk of overuse.
The NACD surveys show that social class plays 
a role in sedative or tranquilliser use. Key 
indicators of socio-economic deprivation, such 
as being unemployed, having low educational 
attainment or fewer years in education, and 
living in social housing, were associated with 
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3higher prevalence for sedative use in the 2002/3 and 2006/7 
surveys. Results from the 2010/11 survey, however, show 
a departure from this general pattern in that prevalence 
rates are now highest among those who are unemployed/
without employment, followed by those in managerial or 
professional occupations. An explanation offered for this 
new pattern is that it reflects a response to the stress of 
deteriorating economic conditions in Ireland. However, 
the fall-out from the recession will have impacted all 
occupational groups and it is difficult to see why managers 
and higher professionals would have resorted to sedatives or 
tranquillisers more than other social groups.
General practitioners everywhere need to be aware that 
the medicine they prescribe may be over used or diverted 
from the intended patient and fall into the wrong hands.4 
A more considered approach by health care professionals 
to alternative (and complementary) treatments where 
appropriate, as well as efforts to inform the general 
population on the safe and effective use of sedatives or 
tranquillisers and on the viability of other treatments, may 
be effective in reducing their use in the future. 
Alex White TD, Minister of State at the Department of Health 
with responsibility for primary care, is considering imposing 
additional controls on the main sedatives and tranquillisers, 
such as benzodiazepines and ‘Z-drugs’. The legislative 
amendments being considered include the introduction of 
an offence of unauthorised possession, as well as controls on 
the import and export, of such drugs.8 It is also proposed to 
tighten the prescribing and dispensing rules applying to these 
drugs. One of the main challenges in formulating policy to 
reduce the misuse or over-use of these medicines is doing so 
in a way that does not interfere with appropriate use. 
Anti-depressants 
An anti-depressant is a prescribed medicine used to alleviate 
medical conditions known as mood disorders (which include 
major depression, chronic depression and anxiety disorders). 
Two examples of anti-depressants are serotonin re-uptake 
inhibitors (SSRIs) and serotonin and noradrenaline re-
uptake inhibitors (SNRIs). The former are used as a first-line 
treatment for depression, while the latter are used to treat 
patients who do not respond to first-line treatment. 
Key findings: anti-depressants 
 ■ In 2010/11 the prevalence rates among adults (aged 
15–64 years) were 10% for lifetime use, 5% for last-year 
use and 4% for last-month use. The rate for last-month 
use increased by 29% since the 2006/7 survey.
 ■ Prevalence rates for women were higher than those  
for men on all three measures: lifetime use (13% vs 8%), 
last-year use (6% vs 4%) and last-month use (5% vs 2%).
 ■ The lifetime rate for men increased by 41% since the last 
survey, while the rate for women was unchanged. The 
last-year prevalence rate for men increased by 33%, and 
the rate for women was unchanged. Overall, the gap 
between men and women in terms of lifetime and last-
year rates has narrowed. 
 ■ Lifetime rates for older adults increased by 21%,  
from 11% in 2006/7 to 13% in 2010/11. No statistically 
significant changes were found over time among  
young adults. 
 ■ The median age at first use was 30 years, two years 
earlier than the median age reported in 2006/7, and was 
lower for women (30 years) than for men (34 years).
 ■ The vast majority (92%) of current users reported taking 
anti-depressants on 20 or more days in the month before 
the survey, and 99% reported getting the medicine on 
prescription from a doctor.
 ■ Prevalence rates were highest for those who were 
dependent long-term on social assistance, and lowest for 
professionals and managers.
 ■ Prevalence rates were higher for people who were 
separated, divorced or widowed than for married or  
co-habiting people. 
(Justine Horgan, NACD, and Jean Long)
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tranquillisers and anti-depressants results. Bulletin 6. Dublin: 
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2. Phillis JW and Wu PH (1982) The effect of various centrally 
active drugs on adenosine uptake by the central nervous 
system. Comparative Biochemistry and Physiology, 72(2): 
179–187.
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6. Department of Health and Children (2002) Benzodiazepines: 
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4Monitoring centre report reveals latest 
drug trends in Europe 
The European Monitoring Centre for Drugs and Drug 
Addiction (EMCDDA) published its annual report 2012 on 
the drugs situation in Europe in November.1 According to 
the report, we may be entering a new era in which heroin 
will no longer play such a central role in Europe’s drugs 
problems. The number of new heroin users is declining in 
several countries, while access to substitution treatment 
for opioid (mostly heroin) users has risen. There is a wide 
range of new psychoactive substances available and the 
drugs market is changing rapidly. The stimulant market is 
particularly complex. Cocaine, amphetamines and ecstasy 
are still the most important stimulants but a number of new 
synthetic drugs, such as cathinones, are becoming more 
significant. The EMCDDA says: ‘It is critical that we better 
understand the health and social impact of these emerging 
trends and develop measures to reduce demand. To do this 
better forensic and toxicological analysis is essential, as is the 
need to proactively engage with those most at risk.’
The drugs situation described in the report is presented 
below under a series of headings.
Cannabis
 ■ Cannabis is still Europe’s most commonly consumed 
illicit drug. One in five adults aged 15–64 have tried 
cannabis at some point in their lives. Most countries 
report that cannabis use is stabilising or decreasing. Of 
the countries which have recorded the highest level of 
last-year prevalence among young people (aged 15–34) 
over the past decade, only Italy recorded an increase.
 ■ Around 1% of adults, three-quarters of whom are 
aged 15–34 use cannabis daily or almost daily. There 
is increasing awareness that dependency is a possible 
consequence of cannabis use and the number of 
individuals seeking help because of their cannabis use is 
growing in some European countries.
 ■ Cannabis resin seizures declined in 2010 after a steady 
increase in the previous decade. The amount of cannabis 
seized continued to decline and the 560 tonnes recorded 
in 2010 was a new low.
 ■ Europe is now an important producer of cannabis. The 
overall trend is toward ‘import substitution’, that is, 
imported cannabis products being replaced by herbal 
cannabis grown inside Europe’s borders.
Opiates (mainly heroin)
 ■ More than 200,000 (48%) clients who entered drug 
treatment in 2010 reported opioids, mainly heroin, as 
their primary problem drug. 
 ■ In some countries clients cited other opioids as their 
primary drug more often than heroin. These include 
fentanyl in Estonia, buprenorphine in Finland, and other 
opioids in Denmark, Latvia and Austria.
 ■ Analysis of data in 24 countries on opioid users entering 
treatment for the first time in their lives showed a 
decrease from 61,000 in 2007 to 46,000 in 2010. The 
average time lag between first opioid use and first 
treatment entry is about nine years, so recent decreases 
in the number of heroin users entering treatment for 
the first time should at least partly reflect a reduction in 
heroin incidence that occurred some time ago. 
 ■ Most EU countries reported an upward trend in drug-
induced deaths between 2003 and 2008, followed by 
stable numbers in 2009, with provisional data for 2010 
pointing to an overall decrease in such deaths. 
 ■ Around 36% of those entering treatment for opioid 
use in 2010 reported injecting. The rate varies greatly 
between countries, from 7% in the Netherlands to 94% 
in Latvia, while data from most countries show a steady 
decrease from 2000. In eastern European countries 
injection is still the main route of administration. 
 ■ While the rate of HIV transmission among drug users 
continues to decrease, Greece and Romania have 
reported outbreaks of HIV infection, with a local 
epidemic among injectors in Athens.
 ■ The EMCDDA estimates that about 1,830 people died 
of HIV/AIDS attributable to drug use in the EU in 2009, 
with almost 90% of these deaths occurring in Spain, 
France, Italy and Portugal.
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5 ■ An estimated 696,000 opioid users were in receipt of 
substitution treatment in 2011, the most common type 
of treatment for opioid dependence in Europe, with 
medium term trends showing a continuous increase 
since 2003. About half of all problem opioid users in 
Europe have access to substitution treatment, but some 
countries have considerably lower coverage levels: 
Greece (28%), Lithuania (17%), Slovakia (12%), Poland 
(8%) and Latvia (2%). 
 ■ Latest figures for seizures and drug-law offences point 
to an overall decrease in heroin supply. Around 55, 000 
seizures resulted in the interception of 19 tonnes of 
heroin in 2010, compared with 56,000 seizures and 24 
tonnes in 2009.
Cocaine
 ■ Cocaine remains the second most commonly used illicit 
drug in Europe, although high levels of cocaine use 
are observed only in a small number of mostly western 
European countries.
 ■ Around 15% of drug users entering treatment report 
cocaine as their main problem drug.
 ■ With the exception of Ireland, where the situation has 
stabilised, the countries most affected by cocaine use 
among young adults (aged 15–34) reported a decline 
in last-year use of this drug by this age group in the last 
country survey.
 ■ The countries reporting the highest last-month 
prevalence among young people were Spain, the UK, 
Cyprus and Italy.
 ■ Some countries reported that the number of cocaine-
related hospital emergencies was three times higher in 
recent years than it had been at the end of the 1990s.
 ■ The number of cocaine seizures fell slightly to around 
88,000 in 2010 from 100,000 in 2008.
Other stimulants and new psychoactive substances
 ■ The European Early Warning System (EWS) identified 24 
new psychoactive substances in 2009, 41 in 2010 and 
49 in 2011. The EWS has already identified over 50 new 
substances in 2012, the largest number ever reported 
in a single year. The two largest drug groups monitored 
by the EWS are synthetic cannabinoids (such as found 
in ‘Spice’) and synthetic cathinones (e.g. mephedrone, 
MDPV) which mimic the effects of other stimulants 
(including cocaine).
 ■ While overall last year use of amphetamines among 
young adults is stable or declining, crystal meth use 
appears to be increasing. Germany, Estonia, Latvia 
and Austria are among the countries that have seen 
significant increases in seizures of the drug between 
2009 and 2010. 
 ■ Deaths linked to use of the stimulant drug 
4-methylamphetamine (4-MA), which is not currently a 
controlled drug, and reports of seizures in 14 European 
countries have prompted a risk-assessment exercise by 
experts from a number of European agencies. 4-MA 
belongs to the group of synthetic phenethylamine drugs 
and is sold on the illicit market, usually mixed with 
amphetamine.
 ■ Use of ecstasy (MDMA) is concentrated among young 
adults. Of 2.0 million adults who reported using the 
drug in the past year, 1.5 million were in the 15–34-year 
age group. The proportion of MDMA in tablets sold as 
ecstasy had been declining in recent years owing to the 
success of measures to prevent diversion of precursor 
chemicals, but MDMA has reappeared and is increasing 
as manufacturers identify new precursor chemicals. 
 ■ The most recent snapshot study (January 2012) 
identified 693 online shops purportedly selling 
psychoactive products, with three natural products – 
kratom, salvia and hallucinogenic mushrooms – the most 
frequently sold ‘legal highs’. There were 170 of these 
shops in January 2010. The snapshot identified a marked 
rise in the availability of synthetic cathinones, suggesting 
that online operators are seeking a replacement for 
mephedrone, now banned in the EU.
Responding to drug use in European prisons
It is estimated that around 635,000 people were held 
in penal institutions in the EU as at September 2010, 
compared with around 582,000 in 2001. A new EMCDDA 
report2 published alongside the annual report examines 
the provision of drug-related services in European prisons, 
including counselling, treatment of dependence and the 
prevention of infectious diseases. Lifetime prevalence levels 
for heroin use among prisoners in 13 of the 17 countries 
surveyed were between 15% and 30%; the rate is less than 
1% for the general population. Some prisoners initiate drug 
use or begin to engage in more harmful practices (e.g. 
sharing injecting equipment) while in prison. Overcrowding, 
poor hygiene and a lack of healthcare provision affect many 
prisons, and contribute to the overall poor health status 
found in inmates. 
The report notes that many countries have scaled up the 
provision of interventions within prisons, particularly of 
substitution treatment for those who are opioid dependent. 
However, prisons rarely offer a standard of care equivalent 
and comparable to that provided to the wider community. 
‘Penitentiary healthcare has in the past decade increasingly 
been recognised as part of public health care’, says the 
report. There is a need to improve continuity of care for 
prisoners on their release when the risk of overdose death 
is extremely high because of reduced tolerance. The report 
highlights the need for pre-release counselling and overdose 
prevention training.
(Brian Galvin)
1. European Monitoring Centre for Drugs and Drug  
Addiction (2012) Annual report 2012: the state of  
the drugs problem in Europe. Luxembourg:  
Publications Office of the European Union.  
www.emcdda.europa.eu/publications/annual-report/2012
2. European Monitoring Centre for Drugs and Drug  
Addiction (2012) Prisons and drugs in Europe: the  
problem and responses. Luxembourg: Publications  
Office of the European Union.  
www.emcdda.europa.eu/publications/selected-issues/prison
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6Prevalence of alcohol consumption and 
alcohol-related harm in Ireland
On 24 September 2012, the National Advisory Committee 
on Drugs (NACD) published the main findings on alcohol 
consumption and alcohol-related harm among adults 
in Ireland from the 2010/11 general population drug 
prevalence survey.1 This is the first NACD drug prevalence 
survey to include a comprehensive series of questions on the 
rates and patterns of alcohol consumption and on alcohol-
related harm. The survey involved a representative sample 
of people aged between 15 and 64 who were interviewed 
during late 2010 and early 2011. Only those aged 18–64 
years (n=4,843) were included in the analysis of the alcohol 
responses as it is illegal for those aged 15–17 to buy alcohol 
and it was not feasible to analyse this group separately due 
to low numbers. 
Frequency and volume of drinking
Eighty-seven per cent of adults aged 18–64 years consumed 
alcohol in the 12 months prior to the survey; these were 
classified as current drinkers. The remaining 13% were 
classified as non-drinkers. Women (15%) were more likely 
than men (11%) to be non–drinkers and respondents aged 
50–64 years (19%) were more likely to be non-drinkers 
compared with 18–24-year-olds (7%). Previous research 
has indicated that people in Ireland consume alcohol less 
frequently than their European counterparts,2 but that when 
they do drink they consume more per drinking occasion 
than Europeans do. In this survey 31% of men and 21% of 
women consumed alcohol at least twice weekly. Those aged 
50–64 years were the most likely to consume alcohol at least 
twice weekly, with 39% of males and 22% of females in this 
age group drinking this often. One quarter of respondents 
(24%) consumed 1–2 standard drinks3 per drinking 
occasion, which is classified as being within low-risk daily 
consumption limits, and this was most common among 
adults aged 50–64 years (34%). Forty per cent of drinkers 
in this survey consumed at least five standard drinks per 
drinking occasion. 
Harmful drinking patterns
The survey examined patterns of harmful drinking using 
three measures: the World Health Organization’s AUDIT-C 
screening tool, which is used to identify people with harmful 
drinking patterns; the frequency of monthly risky single-
occasion drinking (RSOD); and the RAPS screening tool, 
which is used to screen for alcohol dependence. According 
to the AUDIT-C screening tool, half of the population aged 
18–64 years and 58% of current drinkers may be classified 
as harmful drinkers. Among current drinkers aged 18–24 
years, 82% of males and 68% of females scored positive for 
harmful drinking. 
Risky single-occasion drinking (RSOD), commonly described 
as ‘binge drinking’, is defined as consuming at least 75g of 
alcohol on a single drinking occasion; 75g is the equivalent 
of four pints of beer, or seven pub measures of spirits, or 
one 750ml bottle of wine. Half (52%) of all current drinkers 
engaged in RSOD at least once a month in the 12 months 
prior to the survey.
Based on the RAPS screening of behaviours in the 12 months 
prior to the survey, 23% of drinkers reported feelings of 
guilt or remorse after drinking; 24% reported that friends/
family told them about things they said/did that they did 
not remember; 12% reported that they failed to do what 
was normally expected; 2% reported that they needed a first 
drink in the morning. Eighteen per cent (22% males; 13% 
females) of drinkers, had two or more positive scores on the 
RAPS screening tool. Those aged 18–24 years were most 
likely to have two positive scores (43%), compared with 7% 
among those aged 50–64 years.
Alcohol-related harm
One in five drinkers reported that they had experienced 
harm, such as harm to health, work, friendship, or being 
involved in a fight or an accident, in the previous 12 months 
as a result of their drinking, with men almost twice as likely 
as women to report such harm, (26% vs. 14%). Harm 
to health was reported by 13% of drinkers, with 24% of 
18–24-year-olds reporting this harm. Over one quarter of 
respondents (27%) reported that they had experienced 
harm in the previous year as a result of someone else’s 
drinking; these harms include family problems, being 
assaulted and being a passenger with a drunk driver. Those 
who engaged in frequent RSOD were most likely to report 
alcohol-related harm from both their own and others’ 
drinking.
(Deirdre Mongan)
1. National Advisory Committee on Drugs and Public Health 
Information and Research Branch (2012) Drug use in Ireland 
and Northern Ireland Alcohol Consumption and Alcohol-Related 
Harm in Ireland 2010/2011 Drug Prevalence Survey: Bulletin 
7. Dublin: National Advisory Committee on Drugs & Public 
Health Information and Research Branch.  
www.drugsandalcohol.ie/18439
2. TNS Opinion and Social (2010) EU citizens’ attitudes towards 
alcohol. Special Eurobarometer 331. Brussels: European 
Commission.  
http://ec.europa.eu/public_opinion/archives/ebs/ebs_331_en.pdf
3. A standard drink contains 10g of pure alcohol and is the 
equivalent of a half pint of beer/lager, or one pub measure 
of spirits, or one small (100ml) glass of wine.
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7Report of Alcohol Action Ireland 
conference ‘Time Please… For Change’
Alcohol Action Ireland’s conference, ‘Time Please… For 
Change’, held on 1 November brought together a number 
of expert national and international speakers examining key 
initiatives that could make a difference to Ireland’s harmful 
relationship with alcohol. The conference was launched 
by Alex White, Minister for State for Primary Care, who 
said that the National Substance Misuse Strategy would 
be brought to Cabinet in the coming weeks. Dr Jean Long, 
Health Research Board, said that surveys have shown that 
the Irish public supported many of the recommendations 
in the Strategy, including those on minimum pricing and 
advertising restrictions.
Prof Frank Murray, chairman of the alcohol policy group at 
the Royal College of Physicians of Ireland, described how 
mortality rates for liver cirrhosis in Ireland have doubled in 
the last 15 years as a result of alcohol consumption. He said 
that, in order to reduce alcohol consumption and its related 
harms, it is necessary to increase the price of alcohol and 
reduce its availability. Marketing lecturer Pat Kenny told the 
conference that sponsorship was not a type of philanthropy 
by the alcohol industry, but was part of sophisticated 
marketing strategies to normalise alcohol consumption.
Dr John Holmes, University of Sheffield, said that alcohol 
consumption decreased by 3%–8% in Canada following 
the introduction of minimum pricing and described how 
similar plans in Scotland would be expected to cut drinking 
levels by 5.5%. He also stated that minimum pricing has 
a far greater effect on harmful drinkers than on low-risk 
consumers as harmful drinkers consume cheaper products. 
Dr Evelyn Gillan of Alcohol Focus Scotland said that while it 
is partly true that drinking is part of the culture in Scotland 
and Ireland, there has been a huge increase in the availability 
and affordability of alcohol. She also provided an update 
on the industry challenge to the Scottish government’s 
minimum pricing legislation introduced in May 2012. The 
judicial review sought by the industry has been postponed, 
but Alcohol Focus Scotland remained confident that the 
government would defeat the legal challenge. 
Fiona Ryan, CEO of Alcohol Action Ireland, said the country 
cannot afford the financial and human costs that arise from 
alcohol. She said that 27 national charities, community and 
medical representative organisations, many of which deal 
with the realities of alcohol-related harm in communities, 
families, the health system and on the streets, support the 
call for minimum pricing.
Dr Declan Bedford detailed how implementing evidence-
based policy and legislation on drink driving has reduced 
the harms and costs of alcohol on our roads, and Kathleen 
O’Meara of the Irish Cancer Society described how policy 
changes have led to a reduction in tobacco-related harm. 
Copies of the presentations can be accessed at  
http://alcoholireland.ie/2012/time-please-for-change-the-
presentations/. 
(Deirdre Mongan)
Alcohol: increasing price can reduce harm 
and contribute to revenue collection
Alcohol is price sensitive – increasing the cost of alcohol 
reduces its consumption and decreasing the cost of alcohol 
increases its consumption. Price is therefore often used as a 
policy lever to reduce alcohol consumption and its related 
health and social harms. The two main pricing mechanisms 
that can be used to reduce consumption are taxation and 
minimum pricing. There are two types of taxes on alcohol 
in Ireland – excise duties, which vary with the different 
categories of alcoholic drink, and VAT, a uniform rate 
currently set at 23%. Excise duties are normally reviewed 
annually by the Minister for Finance in his Budget. 
Excise duty rates for all alcoholic beverages increased greatly 
in absolute and relative terms between 1950 and 1994; the 
rate for distilled spirits increased by 660%, while that for 
beer increased by 2,570%. Rates increased sharply in the 
1960s and 1970s but the rate of increase slowed after 1980. 
While the rate for beer increased by 1,350% between 1960 
and 1994, it only increased by 120% between 1980 and 
1994.1 However, since 1994 the rate for beer has actually 
decreased by 21% and the rate for wine has decreased by 
4% (Table 1). In 2010 excise receipts amounted to €826 
million.
In general, a reduction in excise duty rates leads to increased 
alcohol sales, lower excise receipts and higher consumption, 
while an increase in excise duty rates leads to reduced 
alcohol sales, higher excise receipts and lower consumption. 
A recent illustration of the link between tax, price and 
consumption is provided by Finland, where in 2004 the 
government reduced alcohol excise duty by an average of 
33% in order to reduce the number of cheap imports. The 
result was an immediate 10% increase in consumption and 
a 17% increase in alcohol-related mortality, equivalent to 
approximately eight additional alcohol-related deaths per 
week.2
The impact of recent excise duty rate changes in Ireland 
is outlined in Table 2. In the December 2009 budget, the 
excise duty rate was decreased by 20–21% for all alcohol 
beverages. This led to increased sales for the alcohol industry 
in 2010 amounting to an additional 2,149,624 litres of 
pure alcohol (equivalent to 8.1 million 700ml bottles of 
vodka). However, the decrease in excise duty rates had a 
detrimental impact both on the exchequer and on public 
health as the excise receipts decreased by €142 million and 
overall consumption increased by 6%. In comparison, the 
42% increase in excise duty rates on spirits in 2003 led to an 
increase of €39 million in excise receipts and a decrease of 
6% in overall alcohol consumption. 
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Beer (per hectolitre 
per cent of alcohol 
exceeding 2.8% volume)
Spirits (per litre of 
alcohol exceeding 5.5% 
volume)
Wine (per hectolitre 
5.5%–15% volume)
Cider (per hectolitre not 
exceeding 5.5% volume)
1994 €19.87 €27.72 €273.00 €44.48
2010 €15.71 €31.13 €262.24 €65.86
Change –20.9% +12.3% –3.9% +48.1%
Table 2 Impact of recent changes in alcohol excise duty rates in Ireland 
Year Change in excise rate Impact on alcohol industry Impact on exchequer Impact on public health
2010 All alcohol ↓ 20–21% Litres sold ↑ 2,149,624 ↓ €141,599,915 Overall consumption ↑ 6%
2008 Wine ↑ 20% Litres sold ↓ 334,206 ↑ €1,130,436 Wine consumption ↓ 6%
2003 Spirits ↑ 42% Litres sold ↓ 1,935,707 ↑ €38,564,205 Spirits consumption ↓ 21% 
2002 Cider ↑ 87% Litres sold ↓ 418,693 ↑ €26,028,516 Cider consumption ↓ 13%
In the European context, Ireland, Denmark, Finland, Sweden 
and the UK are regarded as having relatively high alcohol 
taxes. However, the rates in Ireland are declining in real 
terms and the real burden of alcohol taxation has fallen 
as prices of other consumer goods have risen. Taxation of 
alcohol has in the past been a very important source of state 
revenue. Ireland experienced a clear decrease in alcohol 
tax revenues relative to total state revenues between 1970, 
when its share was 16.5%, and 1996, when it was estimated 
at 5%. A major cause of this decline is that excise duties are 
commonly set as a fixed amount of the local currency, so 
that inflation automatically reduces their value, unless there 
is new legislation to set a new tax level. A solution to the 
tendency of inflation to reduce the tax rate in real terms is 
to provide that the tax rate is tied to a cost-of-living index, 
rising and falling with it, rather than being set at a fixed 
value. This is the case in Australia, where alcohol excise 
duty rates are adjusted every six months in line with the 
Consumer Price Index.3 
It appears that in Ireland tax is no longer employed as a 
means of controlling levels of alcohol consumption and its 
related harm. However, the opposite seems to be the case 
in relation to cigarette smoking, with the rate of excise duty 
on cigarettes increasing by 171% between 1994 and 2010 
(Figure 1). 
Figure 1 Excise duty rates for cigarettes, beer and 
spirits 1994–2010
Coinciding with the excise duty rate increase on cigarettes, 
the number sold decreased by 31%. In addition to the 
positive public health benefits arising from a reduction in 
cigarette smoking, the excise duty receipts increased by 
149% and amounted to €1.1 billion in 2010 (Figure 2).
Figure 2 Number of cigarettes sold and total excise 
receipts 1994–2010
Conclusion
Price regulation is the policy governments most commonly 
use to reduce alcohol consumption. It has a strong evidence 
base for reducing alcohol-related harm, although historically 
it has been used to increase revenue for government, 
rather than for social or public health reasons. Increasing 
excise duty rates increases the price of all alcohol regardless 
of whether it is sold in the on- or off-trade. However, an 
increase in tax may be absorbed by supermarkets and off-set 
by increasing the prices of other goods, and if alcohol is sold 
below cost price the retailer is entitled to a VAT refund on 
the difference between the cost price and the below-cost 
sale price, which deprives the state of revenue. Minimum 
pricing sets a price below which no alcohol beverage 
can be sold and which therefore cannot be undercut; it 
predominantly increases the price of the cheaper alcohol 
sold in supermarkets and mainly impacts harmful and 
younger drinkers. Excise duty and minimum pricing are not 
irreconcilable: a restoration of excise duty to the 2009 levels 
that existed prior to the last government’s 20% cut could 
have earned the government around €170 million in 2011.4 
It is likely that a combination of taxation and minimum 
pricing will have the most beneficial effect on public health 
and will also provide increased revenue to the state at a 
time when harmful use of alcohol is responsible for 88 
deaths each month and costs €3.7 billion annually. In 2009 
the alcohol industry contributed €2.0 billion in the form of 
excise duty and VAT,5 leaving a net cost to the State of €1.7 
billion in costs related to alcohol. 
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9In Budget 2013, presented in December 2012,  
the government increased excise duty on alcohol.  
It remains to be seen what impact this measure  
will have across the board.
(Deirdre Mongan)
1. Osterberg E and Karlsson T (2002) Alcohol policies in EU 
member states and Norway. A collection of country reports. 
Helsinki: European Commission. http://ec.europa.eu/health/
ph_projects/1998/promotion/fp_promotion_1998_a01_27_
en.pdf
2. Mäkelä P and Osterberg E (2009) Weakening of one more 
alcohol control pillar: a review of the effects of the alcohol 
tax cuts in Finland in 2004. Addiction, 104: 554–63.
3. Babor T, Caetano R, Casswell S, et al. (2010) Alcohol: No 
ordinary commodity - research and public policy. Second 
Edition. New York: Oxford University Press. pp. 110–112. 
4. Alcohol Action Ireland (2012) Getting the facts right about 
minimum pricing. Dublin: Alcohol Action Ireland.  
http://alcoholireland.ie/wp-content/uploads/2012/08/
minimum-pricing-fact-sheet.pdf
5. Foley A (2010) The economic contribution of the drinks 
industry. Dublin: Drinks Industry Group of Ireland.  
http://www.drugsandalcohol.ie/14139/
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Which talking therapies (counselling) 
work for drug users with alcohol 
problems?
A collaborative team based at the University of Limerick’s 
Graduate-Entry Medical School has recently completed a 
HRB-funded Cochrane Review of psychosocial interventions 
for problem alcohol use among problem drug users.1 
The review involved collaboration with the UCD School 
of Medicine and Medical Science and NUI Galway and 
was conducted over two years. It describes a gap in the 
research evidence relating to the important question of 
whether clinical interventions that are based on behavioural, 
motivational or social theories of change, and can be 
effective in treating alcohol problems, are also effective for 
patients with coexisting addiction issues. 
What is problem alcohol use and what are psychosocial 
interventions?
Problematic use of alcohol means drinking above the 
recommended safe drinking limits. It can lead to serious 
health issues or dependence. Excessive drinking in people 
who have problems related to use of other drugs is common, 
and often both exacerbates the substance abuse and leads 
to serious health challenges. Psychosocial interventions are 
talking therapies that aim to identify an alcohol problem 
and motivate an individual to do something about it. They 
can be performed by staff with training in these approaches, 
a doctor, nurse, counsellor or psychologist, for example. 
Talking therapies may help people reduce their drinking, but 
their influence on people who have problems with other 
drugs is not known. In undertaking this review, we wanted 
to see whether talking therapies impact on alcohol problems 
in drug users. In particular, we wanted to evaluate data from 
published randomised trials with respect to talking therapies 
focused on alcohol drinking in adult users of illicit drugs 
(mainly opiates and stimulants).
Studies reviewed and conclusions made
We found four relevant studies that involved 594 adults 
(over the age of 18 years) with drug problems. One 
study looked at training in cognitive-behavioural coping 
skills versus 12-step facilitation. One study evaluated 
brief intervention versus treatment as usual. Another trial 
investigated motivational interviewing (group and individual 
format) versus hepatitis health promotion, while the final 
paper reported details of brief motivational intervention 
versus assessment only.
In summary, the studies were so different in their design and 
implementation that their results could not be combined; it 
therefore remains uncertain whether talking therapies affect 
alcohol consumption in people who have problems with 
other drugs. In essence, this is because of the low quality 
of the evidence. In addition, it remains uncertain whether 
talking therapies for drinking affect illicit drug use in people 
who have problems with other drugs. There was not enough 
information to compare different types of talking therapies. 
Many of the studies did not account for possible sources 
of bias; more high-quality studies, such as randomised 
controlled trials, are needed to answer this question.
The knowledge gained in this review will now form part of 
the baseline information for an initiative which develops 
this topic further – PINTA-lite – a feasibility study integrating 
addiction treatment and primary care which will develop an 
evaluation of a psychosocial intervention for polydrug use. 
This three-year project is led by a team at UL’s Graduate-
Entry Medical School and involves academic, clinical, and 
policy experts responsible for planning and delivery of 
addiction care and primary care, and international experts 
on problem alcohol use in primary care and on the role 
of primary care in addressing the needs of vulnerable 
populations.
(Jan Klimas)
1. Klimas J, Field C-A, Cullen W, O’Gorman CSM, Glynn LG, 
Keenan E et al. (2012) Psychosocial interventions to reduce 
alcohol consumption in concurrent problem alcohol and 
illicit drug users. Cochrane Database of Systematic Reviews, 
11. Published online 14 November.  
www.ncbi.nlm.nih.gov/pubmed/23152270
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The role of alcohol in rape cases in Ireland
A Rape Crisis Network Ireland (RCNI)1 submission to the 
Joint Oireachtas Committee on Justice, Defence and Equality 
reported on the issue of ‘Gratuitous violence arising from 
alcohol and substance abuse’.2 The submission states: 
‘Whereas there is little evidence to indicate that better 
recognised drugs, such as Rohypnol and GHB are used with 
regularity to facilitate rape, the high involvement of alcohol 
in Irish rape cases, including rape involving victims who 
were too intoxicated to consent, suggests that alcohol is a 
very common drug used to facilitate rape’ (p.3).
The submission cites Rape and justice in Ireland (RAJI), a 
study published in 2009 that identified a high level of 
alcohol involvement in reported and/or prosecuted rape.3 
Acknowledging that alcohol involvement in rape is not 
unique to Ireland, the submission states that ‘the levels 
of binge drinking [in Ireland] on the occasion of the rape 
are extraordinarily high compared to European and North 
American states’ (p.3). Data cited from the RAJI study 
include the following:
 ■ 45% of complainants and 40% of suspects of reported 
rape between 2000 and 2005 in Ireland had been binge 
drinking on the occasion of the rape.
 ■ Of those on trial for rape whose alcohol consumption 
was known, nearly 90% of defendants had been binge 
drinking.
 ■ As many as 10% of all reported rape cases in Ireland 
involved a complainant who was incapable of offering 
consent due to alcohol consumption. (p.3)
According to the submission, young people appear to be 
particularly at risk, with half of all reported rapes in Ireland 
between 2000 and 2005 involving a victim under 25, and 
33% of those accused of rape in the same period being 
under 25 (p.3).
The submission argues that the widespread societal 
acceptance of alcohol consumption in Ireland diminishes 
recognition of alcohol as a potential date-rape drug. The 
submission cites one study where mock jurors normalised 
the use of alcohol in socio-sexual interaction, even where 
alcohol was administered surreptitiously. However, the 
same study found that when alcohol was replaced with a 
more commonly recognised date-rape drug such as GHB or 
Rohypnol, such behaviour elicited a ‘strong recognition of 
rape from participants’ (p.4).
Applying the lessons from this research to the Irish context, 
the RCNI submission suggests that in Ireland the tolerance 
for the use of alcohol to facilitate sexual interaction 
diminishes the perceived ‘seriousness of sexual violence 
facilitated by alcohol and the culpability of perpetrators of 
sexual assaults and rapes against intoxicated victims’ (p.4). 
Although there is no research in Ireland on jury deliberation 
in rape cases, citing the findings of international research 
that juries are more likely to assign blame to intoxicated 
victims of rape, the submission suggests that ‘it is possible 
that victim alcohol consumption is a contributing factor in 
the low rate of rape conviction’ in Ireland (p.4).
The RAJI study found that victims who had consumed 
alcohol at the time of the rape were likely to self-blame 
and that they were also likely not to report the rape, or 
to withdraw their complaint ‘due to expected negative 
reactions from services’ (p.5).
The RCNI submission makes a number of recommendations, 
including the following;
 ■ Alcohol marketing should be controlled through 
legislation ‘in particular where it is targeted at young 
people and/or presents alcohol consumption as linked to 
sexual success’.
 ■ Broad educational campaigns should target and dispel 
inaccurate alcohol expectancies in order to reduce 
aggressive sexual behaviour in men and facilitate better 
recognition of sexual disinterest and refusal. Such 
education programmes should also affirm that ‘alcohol 
consumption is never a justification for coercing or 
forcing sex on an unwilling partner’.
 ■ ‘There is a need for mock-jury studies in Ireland to 
establish the extent to which victim-blaming attitudes 
influence jury decision making.’ (p.6)
The submission also strongly endorses the recommendations 
of the National Substance Misuse Strategy with regard to 
reducing the supply of alcohol to young people.4 
(Johnny Connolly) 
1. The RCNI is the representative, umbrella body for Rape Crisis 
Centres, which provide free advice, counselling and support 
for survivors of sexual abuse in Ireland. See www.rcni.ie
2. Rape Crisis Network Ireland (2012) RCNI submission to the 
Joint Oireachtas Committee on Justice, Defence and Equality, 
on the issue of gratuitous violence arising from alcohol and 
substance abuse. Galway: Rape Crisis Network Ireland.  
www.rcni.ie/rcni-submissions.aspx
3. Hanly C, Healy D and Scriver S (2009) Rape and justice in 
Ireland: a national study of survivor, prosecutor and court 
responses to rape. Dublin: The Liffey Press. 
4. Department of Health (2012) Steering Group report on a 
National Substance Misuse Strategy. Dublin: Department of 
Health. www.drugsandalcohol.ie/16908
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What makes for a ‘good’ drugs policy?
In recent months a slew of documents outlining what 
makes for a ‘good’ drugs policy have appeared. Two sets of 
guidelines have emanated from the NGO sector, at EU and 
international level, and two from governmental sources – 
the Council of Europe and the US government. A study of 
the principles and criteria as summarised in the table below 
highlights the differing perspectives and priorities of the 
different entities.
Just two principles are explicitly mentioned in all four 
guidelines – the need both to recognise human rights and 
to focus on public health. Two other principles are referred 
to either explicitly or implicitly in all four documents – the 
need for a co-ordinated or integrated response, and the 
need for evidence-based policy. However, the interpretation 
of these terms varies. For example, the EU’s Civil Society 
Forum on Drugs (CSFD) emphasises the ‘right to health care’ 
of all EU citizens, while the US government policy guidelines 
foreground the need to protect the ‘human rights of all 
citizens’, including children and drug users. 
The omission of certain principles from various guidelines is 
also instructive. All guideline documents, except for those 
published by the White House’s Office of National Drug 
Control Policy (ONDCP), highlight the need to focus on 
vulnerable groups and to promote their social inclusion, as 
a preventive measure. Both sets of guidelines published by 
governmental sources call for compliance with international 
treaties, while neither set of guidelines issued by NGO 
bodies refer to international policy instruments. Both sets 
of NGO policy guidelines call for a full role for civil society 
in developing and implementing drug policy. On the other 
hand, the Council of Europe’s policy guidelines recommend 
a limited role for civil society – consultation in order to tap 
into the experience, and dialogue as a means of containing 
conflict; the US government’s policy guidelines do not 
identify any role for civil society. 
Finally, principles put forward by one organisation and not 
mentioned by others tend to emphasise that organisation’s 
priorities. Thus:
 ■ International Drug Policy Consortium: the principle of 
harm reduction to be applied not only when addressing 
drug use but also when tackling drug markets;
 ■ Office of National Drug Control Policy: ensuring access 
to medication-assisted therapies, protecting citizens 
from drugs and disrupting drug trafficking reflect the 
US government’s twin emphases on public health and 
public safety; and
 ■ Pompidou Group: coherence between policies on illegal 
and legal psychoactive substances, and other forms 
of addiction and dependency, reflect a recognition 
of growing polydrug use and findings from addiction 
research and neurobiology, which indicate that 
substance abuse and other addictions are inter-related. 
(Brigid Pike)
Summary of principles or criteria for a ‘good’ drugs policy*
Principles/Criteria
CSFD  
(EU-based NGOs) 
IDPC  
(International NGO)
ONDCP  
(USA)
Pompidou Group 
(Council of Europe)
Human rights Human rights must be 
fully respected in drug 
policies and practices, 
particularly Europeans’ 
right to health care.
Drug policies and 
strategies need to be 
fully compliant with 
international human 
rights standards.
Protect human rights – 
of all citizens including 
children and drug-
involved offenders.
An approach based on 
human rights
Public health focus Drug policies and 
practices must be 
focused on public 
health.
New or revised drug 
laws need to be 
carefully drafted to 
support, instead of 
undermine, health and 
social programmes. 
They should authorise 
and encourage 
public-health and 
harm reduction 
interventions.
Integrate prevention, 
treatment, and 
recovery support 
services into public 
health systems.
The public health 
angle
Co-ordination/
Integration
Drug policies and 
practices must be 
integrated. √
Address the drug 
problem as a shared 
responsibility (i.e. 
international co-
operation).
Transversality
Creating structures for 
co-operation and co-
ordination
Evidence-based Drug policies and 
practices must be 
evidence-based.
Drug policies and 
strategies need to be 
based on an objective 
assessment of priorities 
and evidence.
√
Evidence-informed 
policy approaches
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Principles/Criteria
CSFD  
(EU-based NGOs) 
IDPC  
(International NGO)
ONDCP  
(USA)
Pompidou Group 
(Council of Europe)
Balance Drug policies and 
practices must be 
balanced, reflecting 
the multi-disciplinary 
nature of the drugs 
issue.
Ensure balanced, 
compassionate, and 
humane drug policies.
Balanced approach 
between demand 
reduction and supply 
reduction.
Focus on vulnerable 
groups
Drug policies should 
refocus their attention 
on the needs of 
vulnerable groups.
Drug policies and 
strategies need to 
seek to promote the 
social inclusion of 
marginalised groups.
Targeting vulnerable 
groups
A role for civil society Civil society should 
be meaningfully 
involved, and funded 
and supported 
to participate, in 
national and EU drug 
policy planning, 
implementation, 
monitoring and 
evaluation.
Drug policies and 
strategies need to 
work to build open 
and constructive 
relationships between 
governments and civil 
society.
Consultation with civil 
society is a source 
of ideas, innovative 
proposals and 
potential support, 
and dialogue can be a 
means of dealing with 
conflicts emerging 
in course of policy 
implementation.
Evaluation An essential element of 
effective drug policy
√
Monitoring and 
evaluation
Criminal justice 
system and drug 
users
Focus on drug-related 
services within criminal 
justice system, e.g. 
diversion, alternatives 
to custody, continuity 
of care.
Reform criminal justice 
systems to support 
both public health and 
public safety
Demand reduction Renew focus on 
evidence-based 
demand reduction, 
including prevention, 
early intervention, 
treatment, 
harm reduction, 
rehabilitation and 
social reintegration.
Reduce drug use 
to reduce drug 
consequences
International 
instruments
Support the UN drug 
conventions
Taking into account 
international 
instruments
Policy planning and 
implementation
Description of the 
activities that the 
government will 
pursue and support to 
meet these objectives;
Clear identification 
of the role of 
departments or 
agencies responsible 
for these activities and 
coordination between 
them;
Amount of resources 
made available by 
the government 
to support these 
activities;
Articulation of the 
scope and timescale 
of the strategy, and 
evaluation of progress.
Building institutional 
support
Efficiency and 
effectiveness
Creating structures for 
co-operation and co-
ordination
Initiating and 
managing change
What>makes>for>a>‘good’>drugs>policy?>(continued)
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Principles/Criteria
CSFD  
(EU-based NGOs) 
IDPC  
(International NGO)
ONDCP  
(USA)
Pompidou Group 
(Council of Europe)
Ensuring quality EU minimum quality 
standards for drug 
demand reduction 
measures.
Ensuring quality
Consistency between 
policy and practice √
Taking into account 
international best 
practice
Learning and 
knowledge sharing 
across local, national, 
EU and international 
levels
√ √
Medication-assisted 
therapies
Support and expand 
access to medication-
assisted therapies.
Drugs are illegal 
because their use is 
dangerous
Protect citizens from 
drugs.
Supply reduction Disrupt drug 
trafficking.
Combine policies 
on all psychoactive 
substances
Coherence between 
policies on licit and 
illicit drugs
Harm reduction All drug policies 
and strategies need 
to be focused on 
reducing the harmful 
consequences of drug 
use and markets.
*Key:
√ = principle/criteria implicit in the document
Absence of tick symbol = principle/criteria neither specified nor implied in the document
Sources:
CSFD (Civil Society Forum on Drugs) (April 2012) ‘General 
principles for drug policies’ in Proposal to the EU member 
states and the European Commission for inclusion in the new 
EU drugs strategy and action plan. Available at  
www.drugsandalcohol.ie/18220
IDPC (International Drug Policy Consortium) (March 2012) 
‘Chapter 1: Core principles for developing effective drug 
policy’, in Drug policy guide. 2nd edition. Accessed 25 May 
2012 at www.idpc.net 
ONDCP (Office of National Drug Control Policy) (May 2012) 
‘Principles of modern drug policy’. Accessed 25 May 2012 at 
www.whitehouse.gov/ondcp/policy-and-research/principles-
of-modern-drug-policy.
Pompidou Group (December 2011) Policy paper providing 
guidance to policy makers for developing coherent policies 
for licit and illicit drugs. Strasbourg: Council of Europe 
Publishing. www.coe.int/T/DG3/Pompidou/Source/
Documents/PolicyPaper_en.pdf
What>makes>for>a>‘good’>drugs>policy?>(continued)
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Southern Regional Drugs Task Force 
stresses ‘humanistic’ approach 
As well as reporting on drug use in counties Cork and Kerry 
during 2011 and detailing the projects funded, together 
with the outputs and outcomes, the co-ordinator and chair 
of the Southern Regional Drugs Task Force (SRDTF) have 
used their 2011 annual report as a vehicle for setting out 
their vision of how the individual should be at the centre of a 
task force’s responses to the illicit drugs problem.1
Innovation and development
Co-ordinator Christ Black reports that, as well as focusing 
on its funded projects, the SRDTF has been involved in 
innovative development work that draws on international 
sources. He suggests this is ‘setting the seeds for a more user 
friendly, person centred and health based approach to drugs 
policy and drugs support’. Initiatives include:
 ■ Developing an effective service user involvement 
(SUI) strategy by sending development workers from 
the SRDTF and the South East RDTF to attend training 
in Scotland, provided by ‘Involving Expertise’, which is 
funded by the Scottish Government to create a culture of 
innovation and continuous improvement in service user 
involvement across all organisations in Scotland. These 
development workers are now rolling out training to 
treatment centres in their task force areas.
 ■ Engaging with third-level students and raising 
awareness of perceived high levels of drinking 
through use of an online, evidence-based resource called 
e-Pub (Electronic Personal Use Barometer), developed 
in San Diego, which allows an individual to assess their 
drinking habits, and incorporates a brief intervention.
 ■ A new style of policing that embraces human rights 
and harm reduction is the subject of a proposal 
being developed by the SRDTF in conjunction with 
the International Drug Policy Consortium (IDPC). The 
proposal encompasses work that the SRDTF has been 
progressing, such as an arrest referral process, and ‘a 
vision that drug users be viewed as having a health 
issue and in need of support, rather than being seen as 
criminals within the criminal justice system’.
Care and nurturing
In a personal introduction to the report, the chair of the 
SRDTF, Peadar King,2 reflects on what the SRDTF does 
and what it should be doing. He contrasts the ‘harsh and 
unsympathetic response to drug producers and consumers’ 
adopted generally around the world following the 
ratification of the 1961 UN convention and its concomitant 
treaties, with the response of civil society, health activists 
and field workers who foreground citizens’ human rights 
and promote harm reduction strategies. King is concerned 
that this focus on human rights and the reduction of harm 
may be undermined by the new wave of managerialism, the 
effects of which he likens to the destructive impact of the 
original UN Convention. He writes:
As with other Task Forces in the country, these types of 
[harm reduction] interventions as well as prevention, 
education, treatment and aftercare are core to the 
work of the Southern Regional Task Force. But it is 
also the case that the emphasis on the bureaucratic 
management of these interventions has increased 
exponentially and this has become a feature of the three 
years of my involvement with this Task Force. This new 
managerialism or what has become known as New 
Public Service Management is not just a feature of drugs 
policy but increasingly is affecting all areas of human 
interaction. This new managerialism has spawned a new 
lexicon, ‘organizational outputs, performance indicators, 
service users, clients’, terms that President Michael D. 
Higgins described at the start of 2012 as inappropriate as 
he urged people to use the ‘language of the heart’. 
(Brigid Pike)
1. Black C (2012) Southern Regional Drugs Task Force: annual 
report 2011. Cork: Southern Regional Drugs Task Force. 
www.drugsandalcohol.ie/18470
2. Peadar King is author of The politics of drugs: from production 
to consumption, Liffey Press, Dublin, 2003.  
www.drugsandalcohol.ie/3690
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‘Drug problems are too complex 
and dynamic for single magic bullet 
solutions’
That is the conclusion of a paper published by the European 
Monitoring Centre for Drugs and Drug Addiction (EMCDDA) 
in October 2012.1 Entitled Users’ voices, the paper contains a 
collection of narratives from substance users in Europe about 
their attempts to control or reduce their consumption.
Evidence shows that the power of psychoactive drugs 
is heavily influenced by users’ norms, values, practices 
and circumstances. Yet, says the paper, there is still a 
tendency ‘to overestimate the pharmacological properties of 
psychoactive substances and underestimate the influences 
of social, psychological and cultural aspects on drug use and 
on individuals’ efforts to control it’.
The purpose of the paper is to provide a channel of 
expression for the ‘enormous heterogeneity’ in the 
experiences of substance users and what helps or hinders 
them as they attempt to manage their cravings.
The review presents quotations gleaned from interviews with 
substance users in 16 countries, including Ireland, between 
1993 and 2012. While some quotations are from chronic, 
long-term and marginalised drug users, others are from 
individuals who have managed to limit their consumption 
or do not fulfil common medical criteria for dependence or 
problem use. The authors identify three key issues, which are 
outlined below. The shaded boxes contain quotations from 
Irish sources used in the report to illustrate the issues. 
Triggers prompting an individual to reduce or stop 
consumption and/or to seek help
According to the authors, ‘help-seeking behaviour by 
substance users remains poorly understood. There are 
no clear, universally applicable, causal explanations of 
how or why some people manage to limit their use of 
psychoactive substances and others do not. Nor can 
researchers accurately explain why certain individuals seek 
help and others do not or predict when they will do so, 
although accessible services clearly play a major part. …The 
quotations collected for this paper lend support to findings 
of a unique study by Patrick Biernacki that compared heroin 
addicts who recovered through treatment facilities with 
those who overcame their addiction without treatment.2 He 
described three main ways in which people resolve to stop 
using drugs’: 
 ■ stopping or limiting use without making a firm decision 
to do so,
 ■ realising the need to change behaviour, often after an 
accumulation of negative experiences, and
 ■ hitting rock bottom or experiencing an existential crisis. 
Positive experiences gained from interventions and 
support
Specialist drug treatment services are important for users 
trying to reduce or stop their substance use, as are the 
support and encouragement of family and friends. Problem 
users who have maintained good relationships with family 
and friends not involved in the world of addiction are more 
able to realise their new identities than those who have not. 
Objective and timely information about risks of substance 
use and the range of available services is also cited as a 
valued resource.
I’m happy that I did it that way [counselling]. I’m not 
dependent on anything now. I don’t need any medication, 
I don’t need any doctor. I need to go to counselling and I 
go to counselling. 
(McDonnell A and Van Hout MC [2010] Maze 
and minefield – a grounded theory of opiate self-
detoxification in rural Ireland. Drugs and Alcohol Today, 
10(2): 24–31)
Recovery is an individual thing. Recovery isn’t just coming 
off methadone, it’s a hell of a lot more than that: it’s 
about occupying time, trying to get back into society, 
trying to get back to the normal things… it’s filling the 
void that the heroin and everything that comes with the 
heroin use, the friends, parties. 
(Van Hout MC and Bingham T [2011] Holding pattern: 
an exploratory study of the lived experiences of those on 
methadone maintenance in Dublin North East. Dublin: 
Dublin North East Drugs Task Force Publications.)
Obstacles that hinder individuals trying to change their 
behaviour
In addition to gaps in provision and support, the 
stigmatising attitudes of others can have a profound impact 
on the lives of people with substance use problems, leading 
to feelings of low self-worth and avoidance of contact 
with non-users. Since the 1960s, researchers have been 
highlighting the barrier effects of social stigma on recovery 
from addiction.3 A large body of research also describes how 
people with the least stake in conventional, mainstream life 
are generally at the highest risk of long-term problematic 
substance use, compelled to remain outside or on the 
margins.4 
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When you’re in the chemist, you’re ducking and diving watching 
to see anyone you know. There is a stigma there; people do look 
down their noses. 
(Van Hout and Bingham, Holding pattern.)
In recent years there has been increased recognition of how 
environmental factors promote consumption behaviours.5 
The most commonly cited is ‘bumping into’ friends who use 
psychoactive substances and living in a social environment where 
such substances are easily available. Another obstacle is inaccurate, 
misleading or subjective information.
We were told that it [methadone] wasn’t addictive…they were 
just giving it out to people, the doctors were just writing scripts 
for money. 
(Van Hout and Bingham, Holding pattern.)
The authors point out that the testimonies gathered present a 
challenge to developing a stock of effective interventions and signal 
how complex ‘giving up’ can be. They stress that the statements 
do not represent the situation of all those attempting to control 
or reduce their consumption, but the statements do make an 
important and universal point about the importance of choice and 
the need for diverse interventions that are sensitive and adapted to 
individual circumstances. 
(Brigid Pike)
1. Olszewski D, Hedrich D and Montanari L (2012) Users’ voices: 
experiences and perceptions of European drug users on controlling their 
drug consumption. Lisbon: EMCDDA.  
www.drugsandalcohol.ie/18490
2. Biernacki P (1986) Pathways from heroin addiction: recovery without 
treatment. Philadelphia: Temple University Press.
3. Goffman E (1963) Stigma: notes on the management of spoiled 
identity. New Jersey: Prentice-Hall.
4. Lloyd C (2010) Sinning and sinned against: the stigmatisation of 
problem drug users. London: UK Drug Policy Commission. Online at: 
www.ukdpc.org.uk/publications
5. Prinzleve M, Haasen C, Zurhold H et al. (2004) Cocaine use in 
Europe – a multi-centre study: patterns of use in different groups. 
European Addiction Research, 10(4): 147–55.
HSE publishes hepatitis C strategy 
The Health Service Executive published the hepatitis C strategy in 
September 2012.1 The strategy contains updated epidemiological 
information on hepatitis C and details of new direct-acting 
antivirals.
The Hepatitis C Strategy Working Group summarised the 
epidemiology of hepatitis C, which is a disease of the liver caused 
by a virus identified in 1989. This viral disease is spread from person 
to person through contact with infected blood or other body fluids. 
Unsterile injection equipment and infected blood or blood products 
are the major risk factors for the transmission of the virus. There are 
usually no symptoms associated with the acute and early chronic 
stages of hepatitis C disease. Chronic infection occurs in 70%–80% 
of adults who are infected with the virus. Symptoms of chronic 
infection may include: ongoing flu-like symptoms, joint pains, 
abdominal pain, loss of appetite, altered bowel habit, mood swings 
and/or an inability to sleep. Complications of chronic hepatitis C 
include liver cirrhosis, liver failure and liver cancer. There are six 
genotypes for hepatitis C; treatment outcomes are dependent on 
genotype and other factors. In Ireland injecting drug users are likely 
to have genotypes 1 or 3.2 Certain factors have been identified as 
increasing the severity of the disease and these are alcohol intake, 
co-infection with HIV or hepatitis B, super-infection with hepatitis A 
and older age at infection. 
The working group reviewed the effectiveness of treatment and 
reported that hepatitis C can be treated with a combination of two 
or three anti-viral agents. The medication used to treat this disease 
includes pegylated interferon, ribavirin and more recently (in 
the USA) the addition of telaprevir or boceprevir. The addition of 
either telaprevir or boceprevir to the existing treatment (pegylated 
interferon and ribavirin) increases the success of the treatment for 
those with genotype 1. When treated with a combination of the 
three anti-viral agents, 80% of the hepatitis C genotype 1 patients 
are likely to experience sustained viral clearance, compared to 50% 
when only the two drugs (pegylated interferon and ribavirin) were 
used. There are contra-indications to hepatitis C treatment which 
include pregnancy; severe depression or other mental illness; renal 
disease; autoimmune disease; and end-stage liver cirrhosis. 
The working group reported that the prevalence of hepatitis 
C among those infected through injecting drug use or the 
administration of blood and blood products was high. For injecting 
drug users the prevalence was between 62% and 81% prior to 
2003 while 1,700 people were infected through blood and blood 
products. The prevalence in the general population is unknown 
but was 0.02% among blood donors between 2007 and 2010 
and was 1% among attendees at antenatal clinics. There are only 
two historic studies that examined the incidence of hepatitis C 
among drug users. One study estimated the incidence of hepatitis 
C among 100 injecting drug users attending treatment in Dublin 
between 1992 and 1998 who had an initial negative test and a 
repeat test within nine months.3 The authors reported that the 
incidence of hepatitis C was 66 per 100 person years. A later 
study reported an incidence of 24.5 per 100 person years among 
a sample (358) of opiate users (including some non-injectors) 
attending treatment in the former South Western Area Health 
Board in 2001/2002.4 Comparisons between these studies are 
difficult as it is not possible to ascertain the proportion of non-
injectors in the sample surveyed in the later study. Studies in 
Ireland identify homeless people, prisoners and asylum seekers 
as being high-risk populations for hepatitis C, largely because a 
high proportion of prisoners and homeless people inject drugs. 
The working group reports that asylum seekers often come from 
countries where hepatitis C is endemic. 
Drug>problems>are>too>complex…>(continued)
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There were 2,800 discharges from acute hospitals with 
a principal diagnosis of chronic viral hepatitis C between 
2005 and 2010 and there were 1,193 discharges with a 
principal diagnosis of primary liver cancer. There were 703 
cases of hepatocellular carcinoma registered by the National 
Cancer Register Ireland between 1994 and 2010. The NCRI 
estimates that 30% of hepatocellular carcinoma cases were 
hepatitis C positive. The liver transplant unit at St Vincent’s 
University Hospital reported that 42 (13.5%) of 311 liver 
transplant cases between 2000 and 2006 had hepatitis C.
The new national hepatitis C strategy makes 36 
recommendations: 8 covering surveillance; 14 on education, 
prevention and communication (through 6 overarching 
themes); 6 on screening and testing; and 8 on treatment 
(through 7 overarching themes).
The recommendations for ensuring accurate surveillance are:
 ■ Ensure laboratory requests for hepatitis C serology 
contain patient identifiers and clinician details. 
 ■ Encourage clinicians to notify newly diagnosed cases 
of hepatitis C and provide relevant information where 
possible.
 ■ Commence enhanced surveillance (including the 
collection of risk factors) for newly diagnosed cases of 
hepatitis C 
 ■ Establish a national register of patients diagnosed with 
hepatitis C 
 ■ Commence appropriate public health follow-up on 
newly notified cases of hepatitis C 
 ■ Estimate the prevalence of hepatitis C and identify risk 
factors among the general population
 ■ Complete a modelling exercise to estimate future disease 
burden and aid service planning
 ■ Conduct follow-up studies amongst injecting drug users 
to identify seroconverters so as to measure incidence 
rate. 
The recommendations for maximising prevention and 
ensuring clear and accurate information are:
 ■ Treat existing drug addiction among injecting drug 
users.
 ■ Prevent transition from smoking heroin to injecting 
heroin and encourage current injectors to move to 
treatment or harm-reduction approaches.
 ■ Improve provision of harm-reduction materials through 
nationwide access to and uptake of comprehensive set of 
materials and appropriate communications with respect 
to language, literacy and accuracy.
 ■ Ensure staff and peer-educators are recruited to pre-
agreed standards and have appropriate training and 
materials to provide accessible and accurate information. 
 ■ Plan and implement a campaign to raise awareness 
amongst those who may previously have been 
diagnosed with hepatitis C or who may have been at risk 
of infection in order that they consider accessing new 
treatment options.
 ■ Regulate services that provide body-piercing, tattooing 
and permanent make-up.
The recommendations for ensuring screening and diagnosis 
are available to the appropriate risk populations in a timely 
manner are:
 ■ Improve availability of and access to facilities for 
screening, testing and diagnosis available in primary 
and community care services with adequate and timely 
laboratory facilities.
 ■ Enhance prison-based services with respect to risk 
assessment, screening and follow up.
 ■ Offer and promote screening for hepatitis C and other 
blood-borne diseases to those who attend services such 
as needle-exchange programmes and other harm-
reduction services.
 ■ Continue targeted antenatal screening for those with 
risk factors for hepatitis C infection and consider the 
evidence for introduction of universal screening at 
regular intervals.
 ■ Ensure the NVRL provide previous tests results to medical 
practitioners who ascertained the patient’s consent.
 ■ Establish guidelines on hepatitis C screening for 
individuals from endemic countries or new entrants to 
the Irish healthcare system.
The recommendations for ensuring that evidence-based 
hepatitis C treatment and other supports are available to 
patients in a timely manner are:
 ■ Ensure governance, evidence-based protocols and review 
is available to diagnose people with hepatitis C and treat 
if required.
 ■ Develop, implement and evaluate a treatment model 
appropriate to the prison setting on a national basis.
 ■ Establish a postgraduate diploma in hepatitis C 
management for physicians and nursing staff.
 ■ Undertake a formal assessment of the needs of 
individuals infected with hepatitis C, other than through 
contaminated blood and blood products, through an 
increased number of clinical nurse specialist posts and 
subsequent needs assessments.
 ■ Develop a role for general practitioners (with special 
qualifications) to monitor hepatitis C treatment in 
primary and community care in consultation with other 
appropriate medical specialists.
 ■ Provide patients, particularly those with chaotic lifestyles 
and other social problems, with practical supports to 
enable them to attend for and adhere to treatment.
 ■ Provide interventions to assess and if necessary reduce 
alcohol intake in patients with hepatitis C.
(Jean Long)
1. Hepatitis C Strategy Working Group or HSE National  
Social Inclusion. (2012) National Hepatitis C Strategy 
2011–2014. Dublin: Health Service Executive.  
www.drugsandalcohol.ie/18325
2. Conroy A, Coughlan S, Dooley S and Hall WW (2003) 
Prevalence of hepatitis C genotypes in Ireland. Irish Journal of 
Medical Science, 172(2, Supplement 1): 15.
3. Smyth B, O’Connor JJ, Barry J and Keenan E (2003) 
Retrospective cohort study examining incidence of HIV 
and hepatitis C infection among injecting drug users in 
Dublin. Journal of Epidemiology and Community Health, 57(4): 
310–311.
4. Grogan L, Tiernan M, Geoghegan N, Smyth B and Keenan 
E (2005) Bloodborne virus infections among drug users in 
Ireland: a retrospective cross-sectional survey of screening, 
prevalence, incidence and hepatitis B immunisation uptake. 
Irish Journal of Medical Science, 174(2): 14–20.
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The first census of homeless persons in 
Ireland
The Central Statistics Office (CSO) has published for the first 
time a comprehensive profile of the homeless population, 
as enumerated in the 2011 census of the population of 
Ireland.1 This article presents a descriptive account of a 
selection of data contained in the report. 
A comprehensive approach to measuring homelessness was 
adopted as part of the census undertaken on 10 April 2011. 
Homeless persons were identified based on where they were 
located on census night. Of the 4,588,252 persons counted 
in the state, 3,808 were either counted in accommodation 
providing shelter for homeless persons or were identified 
sleeping rough (Table 1). 
Table 1 Persons counted in accommodation for the 
homeless and sleeping rough, by sex
Category Male Female Total
Persons in accommodation 2,481 1,263 3,744
Persons sleeping rough 58 6 64
Total 2,539 1,269 3,808
Source: Central Statistics Office (2012)
Accommodation type
 ■ Over 40% (n=1,648) of homeless persons were counted 
in emergency accommodation: 1,117 males and 531 
females. 
 ■ 555 were counted in transitional accommodation: 397 
males and 158 females. 
 ■ 992 were counted in long-term accommodation: 578 
males and 414 females. 
 ■ 344 were counted in mixed accommodation: 250 males 
and 94 females. 
 ■ 206 were counted in what was reported as ‘unknown’ 
accommodation: 139 males and 66 females. 
Persons sleeping rough
The Dublin Regional Homeless Executive (DRHE) on behalf of 
the CSO undertook a count of persons sleeping rough in the 
Dublin area on census night. The count took place between 
3.30 am and 6.00 am through a process of ‘discovery’, that 
is, direct observation of the number of persons physically 
present and sleeping rough in Dublin on that night. Of the 
64 persons counted sleeping rough, 58 were male and 59 
were counted in Dublin. 
Age profile
Almost three quarters of homeless persons (n=2,781) were 
in the 20–59-year age group; 641 were in the 0–19-year age 
group, including 457 children aged 0–14. 
Marital status and the family unit
Among 3,351 homeless persons aged 15 or over, two thirds 
were single, compared to 42% in the general population. 
Just under 6 %( n=189) were married or re-married, 
compared to 48% in the general population. Almost 17% 
(n=561) were separated or divorced, compared to 6% in the 
general population. 
The family unit was defined as a couple with or without 
children or a lone parent with at least one child. There were 
296 family units comprising 905 persons, of whom 498 were 
children. 
Economic and education status
Of the 3,351 homeless persons aged 15 or over, 1,287 
were unemployed and 99 were looking for their first job. 
Twenty-two per cent (n=752) were unable to work due to 
permanent sickness or disability, compared to 4% in the 
general population. 274 homeless persons were in work, 218 
were students, and 186 were retired. 
Forty-nine per cent (n=1,439) of homeless persons aged 
15 to 59 did not have an educational qualification beyond 
lower second-level, compared to 25% in the general 
population. 
General health and disabilities
Just over 60% (n=2,298) of the homeless population 
indicated that their general health was ‘good’ or ‘very good’, 
compared to 89% in the general population. Almost 70% of 
homeless females indicated that their health was ‘good’ or 
‘very good’, compared to 56% of homeless males. 
Almost a third (n=1,179) of the homeless population 
indicated that their general health was ‘fair’, ‘bad’ or 
‘very bad’, compared to 10% in the general population. 
Forty-two per cent (n= 1,581) of homeless persons had a 
disability, compared to 13% in the general population. The 
most common disability was a psychological or emotional 
condition (n=740). 
(Martin Keane)
1. Central Statistics Office (2012) Homeless persons in Ireland: a 
special census report. Cork: Central Statistics Office.  
www.drugsandalcohol.ie/18334
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Mental health among homeless male 
hostel residents in Dublin
Recently published research aimed to determine the 
prevalence of mental illness among residents of a homeless 
hostel in inner-city Dublin.1 The Structured Clinical Interview 
for DSM-IV Axis 1 Disorders (SCID-1) Clinical Version was 
used to collect data from study participants over an eight-
week period in June–August 2010. Of 97 men considered 
as ‘residents’ for the purpose of the study, 38 agreed to be 
interviewed, representing a response rate of 39.2%. 
Of the 38 participants:
 ■ 47.4% were in the 40–54-year age group, 31.6% in the 
26–39-year age group and 21% were aged 55 or over.
 ■ Over half (57.9%) had never married.
 ■ 68.4% had children.
 ■ 73.7% reached secondary level education without 
graduating.
 ■ 92% were unemployed.
A total of 81.6% had a current (last 30 days) Axis 1 
diagnosis; the rate increased to 89.5% for lifetime 
prevalence, when current and past Axis 1 diagnoses were 
combined. Regarding lifetime diagnoses, the rates were 
as follows: 42% depressive disorder, 78.9% substance 
use disorder, 18.4% anxiety/adjustment disorder and 
5.3% psychotic disorder. The most common current and 
past diagnosis was alcohol dependence, with 52.6% of 
participants meeting the criteria for dependence. The 
most common disorders during the past 30 days were 
alcohol dependence 23.7%, opioid dependence and 
major depressive disorder both 18.4% and opioid abuse 
and alcohol-induced depression both 7.9%. According 
to the authors ‘there was considerable comorbidity 
between disorders, with a significant number of residents 
experiencing both mental illness and substance use 
problems’ (p. 25). 
Of those interviewed, 31.6% had been admitted to a 
psychiatric hospital at least once during their lifetime 
and only 23.7% were currently attending an outpatient 
psychiatric or addiction service. The authors note that ‘the 
low number of residents attending services is cause for 
concern’ (p. 25). 
The authors acknowledge the relatively low response rate 
to the study, and report that information provided to the 
research team by the specialist support worker at the hostel 
suggested that some of the 59 men who did not agree to 
be interviewed may have had experience of mental illness. 
They also acknowledge the possibility of selection bias, 
given that the specialist mental health worker at the hostel 
encouraged the men who had mental health problems to 
be interviewed for the study. However, the authors also note 
that, to the best of their knowledge, this was the first study 
undertaken in Ireland to assess the complete spectrum of 
Axis 1 disorders. 
(Martin Keane) 
1. Prinsloo B, Parr C and Fenton J (2012) Mental illness among 
the homeless: prevalence study in a Dublin homeless hostel. 
Irish Journal of Psychological Medicine, 29(1): 22–26.  
www.drugsandalcohol.ie/18235
Research on young people leaving state 
care in North Dublin
Recently published research examined the issues facing 
young people leaving state care in North Dublin.1 The 
research was commissioned by the independent association, 
Empowering People in Care (EPIC). Currently there is no 
statutory obligation to provide aftercare services to people 
leaving state care when they reach age 18, however, the 
Health Service Executive (HSE) provides a discretionary 
package of supports and services to some young people 
who are deemed to be in need. These provisions are made 
under Section 45 of the Child Care Act 1991, which states: 
‘Aftercare services may be provided to young care leavers up 
to the age of 21 or when they finish education.’ 
The bulk of data in this report comes from surveys 
completed by eight aftercare workers on the circumstances 
of 65 young people, including 33 females, who were 
receiving aftercare support in North Dublin. Data were 
collected in two rounds: in May/June 2010 when all 65 
young people were aged 17–18, and again in December 
2010/January 2011 when 34 of the young people were  
aged 19. 
It was reported that 42 of the young people were first placed 
in care because of their parents’ inability to cope or their 
parents’ alcohol and drug problems; 27 were first placed 
in care owing to abuse and neglect. Eleven of the young 
people were first placed in care because of their own alcohol 
and drug use and behavioural difficulties. Seventeen were 
first placed in care when aged five or under.
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Probation Service annual report 2011
The 2011 annual report of the Probation Service was published in August 2012.1  
The introduction to the report describes the role of the service as follows:
The Probation Service is an agency within the Department of Justice and Equality. 
The Service works closely with the Courts Service, the Irish Prison Service (IPS), An 
Garda Síochána, the Irish Youth Justice Service (IYJS), the Parole Board and many 
organisations in the community. …
We generally become involved in the criminal justice process between the trial and 
sanction phases, often in cases where a court requires a pre-sanction assessment 
to assist in deciding on an appropriate sanction. In some cases, the court may be 
considering placing an offender on probation supervision or community service. (p.6)
In 2011, the Service dealt with 14,845 offenders in the community. The statistical 
data provided in the annual report does not provide a breakdown of offenders or 
interventions by offence type. 
(Johnny Connolly)
1. The Probation Service (2012) The Probation Service annual report 2011.  
 Navan: Probation Service. www.drugsandalcohol.ie/18249
Twenty-five of the young people had spent more than 10 
years in care; 22 had spent 1–5 years. Thirty-three spent 
their final placement in foster care, 18 with a relative and 
15 in general foster care; 18 spent their final placement 
in residential care. Twenty-four spent more than five years 
in their final placement, 30 spent 1–5 years and 17 less 
than one year. Twenty-four young people had one care 
placement and 11 had two placements during their time in 
care; eight had more than five placements. Spending time in 
foster care was associated with one placement; in contrast, 
spending time in residential care was associated with more 
than one placement. Females were more likely than males 
to experience multiple placements. Reducing the number of 
different placements was reported by aftercare workers to 
promote stability and positive outcomes for young people. 
At Round 2 of data collection, it was reported that 23 of the 
young people had no accommodation moves in the previous 
20 months, 14 had two moves and 20 have moved three or 
more times. Movement between different accommodations 
was associated with multiple care placements. It was reported 
at Round 1 of data collection that 18 of the young people had 
experienced homelessness at least once in their lives. 
It was reported that 25 of the young people had completed 
their education at junior certificate level, 17 had reached 
leaving certificate level and a further 13 were currently 
attending college, most of whom were studying a post-
leaving certificate course; eight young people had no 
formal educational qualifications. There were reductions 
in the numbers of young people in education and training 
between Rounds 1 and 2 of data collection, and an increase 
in unemployment among the young people. 
At Round 1 of data collection 29 young people were regular 
smokers and 27 were regular consumers of alcohol; at 
Round 2 these numbers increased to 35 regular smokers and 
40 regular users of alcohol. In contrast, there was a reported 
reduction in the use of illegal drugs, from 27 reported users 
at Round 1 to 23 at Round 2. Aftercare workers reported 
an increase from 20 to 25 in the number of young people 
with mental health needs between the two rounds of data 
collection. 
Analysis of the data gathered in Round 2 helped define 
‘positive outcomes’ in terms of seven key aspects of a young 
person’s circumstances while in care and on leaving care  
(p. 51):
 ■ no accommodation moves since Round 1; 
 ■ not being homeless at any time;
 ■ being engaged in further education or training beyond 
secondary school;
 ■ having sat leaving certificate or equivalent;
 ■ having contact with at least one member of birth family 
after leaving care;
 ■ not engaging in risky behaviour; and
 ■ having overall good physical and mental health and not 
using illicit drugs.
It was reported that 29 of the young people in this study 
had achieved 2–4 of the seven outcomes, 24 had achieved 
5–7 and 12 had achieved 0 or 1 outcome. Further analysis of 
the data suggested that when young people remain in the 
same care placement, typically foster care, they experience 
positive outcomes to assist in their transition from state care 
to adulthood. 
Data were collected through interviews with eight of the 
young people. The main issues identified through thematic 
analysis of the data were that the young people were 
concerned with multiple accommodation moves and with 
their mental health needs after leaving care. They identified 
social support as their greatest need and expressed disquiet 
at the speed of transition from care to the community, 
preferring more step-down supported accommodation to 
aid a gradual transition. Overall, they spoke positively about 
the aftercare support they were receiving but had concerns 
about not having access to their support workers during 
out-of-office hours and with the challenges they experienced 
with budgeting. 
The report acknowledges the potential limitation of relying 
on data collected through surveys with aftercare workers, 
whose records may have been incomplete and whose 
perceptions of young people’s circumstances may not have 
been a true representation of their situation. The author 
acknowledges that it would have been preferable to survey 
the young people but that this had been ruled out as it 
would have required a time consuming exercise gaining 
informed consent from a number of agencies that were 
involved in the lives of young people. 
(Martin Keane) 
1. Daly F (2012) ‘My voice has to be heard’: research on 
outcomes for young people leaving state care in North Dublin. 
Dublin: EPIC. www.drugsandalcohol.ie/18294
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NESC report commends city policing 
initiative
A report published by the National Economic and Social 
Council (NESC) as part of its quality and standards in human 
services in Ireland series reviews the various police oversight 
and consultative bodies established by the Garda Síochána 
Act 2005.1 The new regulatory institutions established by the 
Act include the Garda Síochána Ombudsman Commission, 
the Garda Síochána Inspectorate, Joint Policing Committees 
and Local Policing Fora.
Many of these oversight bodies emerged as a response to 
‘revelations about abuse of powers by individual officers’, 
with the net result being a much greater oversight of police 
activity (p.2). However, the report queries their overall 
impact, on both the level and quality of policing and ‘the 
potentially egregious abuses of power’ (p.2). The report 
suggests that ‘these bodies have yet to institutionalise 
procedures that would embed and sustain reform over time’ 
(p.ix). It also poses the more fundamental question as to 
whether the kind of oversight offered by these bodies is 
sufficiently ‘diagnostic’ to uncover the causes of the various 
complaints and problems they were established to address, 
so as to prevent their recurrence.
The report suggests that a more promising route towards 
the improvement of policing standards may be through 
a structured liaison process between gardaí and local 
communities, citing an example of how this has been 
accomplished as part of a local community policing initiative 
established in Dublin’s north inner city. The North Inner City 
Community Policing Forum (CPF) was established in 1999 
to facilitate a co-ordinated strategy in response to drug 
dealing and drug-related anti-social behaviour in the north 
inner city.2 The CPF brings together the local community 
and representatives of the Garda Síochána and Dublin City 
Council. The NESC report concludes that the CPF has been 
a ‘relatively successful model of engagement with citizens 
at a local level’ and that it has fostered a ‘greater culture 
of transparency’ between the community and the gardaí 
involved (p.33). The community, according to the report 
‘now have a more responsive police service and the gardaí 
have been able to tap into confidential information derived 
from the community’ (p.34).
Although highlighting the positive achievements of the 
CPF, the NESC report concludes that, when approaching all 
forms of policing service delivery in Ireland, there is a need 
for a more rigorous process of learning and analysis so as to 
encourage continuous improvement. It advocates a process 
referred to as ‘triple-loop learning’, described as a ‘need for 
learning to take place at a number of levels that reinforce 
each other: the level at which the service is delivered; at 
corporate level; and at the level of regulator or at national 
level’ (p.5). According to the NESC report, because of the 
policing reforms introduced by the Garda Síochána Act 
2005, ‘Ireland has all the “parts” necessary for a well-
functioning system of quality policing… . But these parts 
have yet to be co-opted into a common regime of learning 
that is conducive to greater quality in policing’ (pp.ix–x).
(Johnny Connolly)
1. National Economic and Social Council (2012) Quality and 
standards in human services in Ireland: policing and the search 
for continuous improvement. Dublin: National Economic and 
Social Council. www.drugsandalcohol.ie/18406
2. For a detailed account of the CPF see Connolly J (2002) 
Community policing and drugs in Dublin: the North Inner City 
Community Policing Forum. Dublin: North Inner City Drugs 
Task Force.
Roadside drug testing
The Medical Bureau of Road Safety (MBRS) published its 
Report on roadside drug testing and equipment and related 
matters in October 2012.1 Speaking at the launch, Professor 
Denis Cusack, director of MBRS, said ‘this report provides a 
detailed analysis of all aspects of roadside drug testing’. 
‘Unlike alcohol, there is no legal limit for drugs. Under 
current road traffic law, the Gardaí must be satisfied that 
a driver is under the influence to such an extent as to be 
incapable of having proper control of a vehicle. This  
means that the Garda has to prove the driver impairment  
to the satisfaction of the Court and this can cause difficulties 
in successfully prosecuting such offences’, Professor  
Cusack said.
This report will inform the Road Traffic Bill which is currently 
at draft stage. The Bill will include new roadside impairment 
testing for drug use by motorists. Research is currently under 
way to identify a suitable device for detecting drugs at the 
roadside, similar to that used for detecting alcohol.
The National Drug-Related Deaths Index (NDRDI) at the 
Health Research Board made a substantial contribution to 
the MBRS report by providing a complete census of fatal 
road traffic collisions (RTCs) where the deceased person was 
the driver of the vehicle and had a positive toxicology report 
for an illicit substance. Currently the NDRDI is the only data 
source able to provide comprehensive data on the presence 
of illicit drugs in post-mortem toxicology. In the future the 
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Figure 1 Drugs recorded in post-mortem toxicology reports, vehicle drivers, NDRDI 2004–2009 (n=93)
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NDRDI will be able to monitor trends in drug-related deaths 
and evaluate the effects the new Road Safety Strategy will 
have on preventing these deaths.
The following analysis presents NDRDI data for the period 
2004 to 2009 on RTC deaths among vehicle drivers in 
Ireland where the individual had a positive toxicology for 
one or more illicit drugs at the time of death. In this six-year 
period there were 93 of these deaths recorded by  
the NDRDI. 
Cannabis (38.7%) was the most common illicit drug found 
in the toxicology reports on these 93 individuals, followed 
by cocaine (23.7%) and MDMA (18.3%) (Figure 1).
(Simone Walsh)
1. Cusack D A, Leavy P and Maguire R (2012) Report on 
roadside drug testing and equipment and related matters. 
Dublin: Medical Bureau of Road Safety.  
www.drugsandalcohol.ie/18630
MQI annual review 2011 
The Merchants Quay 
Ireland (MQI) annual 
review for 2011 
was launched on 
14 September 2012 
by journalist and 
broadcaster Miriam 
O’Callaghan.1 
Important new 
initiatives at MQI in 
2011 included the 
Athlone Open Door 
Centre, the new 
10-bed unit at St 
Francis Farm Detox 
facility (opened in 
November 2011) and 
the commencement of renovation works at the Riverbank 
Centre. (This new Centre was officially opened by An 
Taoiseach Enda Kenny in November 2012 – see opposite.)
The outreach worker for the New Communities Support 
Service provided one-to-one support to 112 service users, 
53% of whom were from Poland. The Easy Access Education 
for Homeless People programme engaged with 45 clients 
during 2011: 34 male and 11 female.
MQI’s needle-exchange service recorded approximately 
21,819 client visits in 2011. The report highlights a 
continuing high level of demand for homeless services: 
58,858 meals were provided, with an additional 29,000 
meals provided by the Extended Day Service in association 
with Focus Ireland. The Primary Health Care Services 
provided 3,331 interventions in 2011.
MQI continued to provide the national prison-based 
addiction counselling service to 12 prisons in 2011: 10,293 
individual counselling sessions and 2,830 group attendances 
were recorded during the year. This service is provided by 
26 counsellors. The service also co-ordinates an eight-week 
inter-agency programme at the medical unit in Mountjoy 
for groups of nine clients at a time. Seven groups, totalling 
63 clients, participated in 2011, of whom only four did not 
complete the programme. 
MQI in association with the Midland Regional Drugs Task 
Force and the HSE administer the Midlands Family Support 
and Community Harm Reduction Service, providing 
outreach and working with families of those actively using 
drugs in that task force region. The family support service 
provided 140 group sessions and 505 individual sessions, in 
addition to 723 supportive phone calls. The harm reduction 
service provided needle-exchange services and engaged in 
4,000 one-to-one client interventions during 2011. 
Roadside>drug>testing>(continued)
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The Midlands Traveller-Specific Drugs Project worked with 
38 clients and engaged in 1,187 support sessions. Athlone 
Open Door Centre, for which MQI assumed operational 
responsibility in January 2011, recorded 1,415 visits and 
provided 400 meals, with an average of 44 clients per 
month.
The services offered by MQI and the numbers of people 
accessing them in 2011 are shown below.
(Vivion McGuire and Ita Condron )
1. Merchants Quay Ireland (2012) Annual review 2011. Dublin: 
MQI. www.drugsandalcohol.ie/18372
Service Type of intervention Activity in 2011
Needle-exchange and 
health-promotion 
services
Promotes safer injecting techniques  
HIV and hepatitis prevention 
Safe sex advice 
Information on overdose 
Early referral to drug treatment services
4,051 used needle-exchange services, of whom 492 
were new clients
1,220 safer injecting workshops
Stabilisation services Methadone substitution
Gateway programme
18 service users
795 service visits 
Integration 
programmes
Access to transitional accommodation 
Ballymount House
Leixlip House with Respond Housing 
Association
3 residents (annual average) 
9 admissions, with an average of 5 clients in the 
house for an average tenancy of 5 months 
Training and work 
programmes
FÁS Community Employment scheme 86 participants
Of the 35 who completed FÁS placements at MQI, 
2 secured permanent employment, 7 moved to 
further education
High Park 17-week, drug-free residential programme 
including individual counselling, group 
therapy, educational groups, work 
assignments and recreational activities
50 participants (of whom 4 were admitted for 
detoxification)
3 clients completed detox 
24 clients completed the full programme
St Francis Farm Residential programme – reduced from 
a 6-month to a 14-week programme in 
October 2011, in conjunction with a new 
4–6-week detox facility on site
40 participants
15 clients completed three months or more
23 clients part-completed the programme
MIQ>annual>review>2011>(continued)
Taoiseach officially opens Riverbank Centre
Taoiseach Enda Kenny preformed the 
official opening of MQI’s new Riverbank 
Centre at 13 Merchants Quay, Dublin 8, 
on 21 November.
The Riverbank Open Access Centre 
offers three free meals a day in a 
respectful non-judgemental atmosphere. 
Additional services provided include a 
primary care centre offering medical 
and dental facilities, as well as help 
with the practicalities of ending 
homelessness and addiction.
Tony Geoghegan, MQI director, said 
he was ‘not surprised’ that the new 
centre, which has almost double the 
capacity of the old centre, has seen 
demand increase to fill it up almost 
immediately. ‘We have known from 
experience there is a social cost to the 
recession’, he said, ‘it was the same in 
the 1980s.’ 
Mark Kennedy, head of day services, 
said the new primary care services are 
a great asset. Many foreign nationals 
experience difficulty in accessing HSE 
services, he said, and the project was 
particularly grateful to a dentist who 
offered his services for free. 
(Vivion McGuire)
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From Drugnet Europe
Selected issues 2012
Cited from Drugnet Europe, No. 80, October–December 
2012
Prisons and drugs in Europe
In a new review published alongside the Annual report, 
the EMCDDA provides insight into drug use in the prison 
population and the efforts made at European and national 
level to improve prisoners’ rights and health. While many 
countries have scaled up the provision of interventions 
within prisons (e.g. substitution treatment), these institutions 
still do not offer a standard of care equivalent or comparable 
to that provided to the wider community. The report 
presents progress now being made in several countries 
towards promoting ‘equivalence of care’ and closing this 
‘treatment gap’.
Pregnancy, childcare and the family
Families and the related issue of drug users with parental 
responsibility are analysed in this new study. The report 
finds that, although those with drug problems do not 
necessarily make bad parents, they are likely to require 
additional support. The report concludes that treatment 
services, in particular, must be sensitive to the needs of these 
individuals, as worries about childcare or child protection 
can act as a barrier to seeking help.  
www.emcdda.europa.eu/publications/selected-issues
Resources
Reviews by Isabelle Giraudon and Julián Vicente in Drugnet 
Europe, No. 80, October–December 2012
Preventing opioid overdoses in Europe: a critical assessment 
of known risk factors and preventative measures
This study focuses on the individual, situational and 
organisational risk factors linked to overdoses and how they 
can be modified to reduce fatal outcomes. Key risk and 
protective factors were categorised for the study and their 
efficacy plus the factors facilitating or impeding overdose 
prevention were critically discussed by an expert panel. 
The review evidenced that many interventions may reduce 
overdose, particularly in settings where the drug user is in 
contact with treatment or emergency services. It also shows 
that specific interventions are proven to be effective (e.g. 
pharmacological treatment). At the population level, where 
many drug users are not in contact with services, overdose 
reduction depends on behavioural change (e.g. avoiding 
the mixture of opiates and depressant drugs). The study 
concludes that overdose prevention involves personal and 
societal issues which call for multifaceted interventions.
Available at www.drugsandalcohol.ie/18701
Analysis of the data sources, numbers and characteristics of 
cocaine-related DRD cases 
Nineteen countries (nine of which submitted data), 
responded to an EMCDDA survey on cocaine related deaths. 
The identification and coding of cocaine-related deaths 
varies across registers and across countries. The study shows 
that during the 2000s there was an increasing upward trend 
in the numbers of these deaths, followed by a decline in 
most countries. By far, most deaths were reported in the UK 
(2 400 deaths over 1998–2009) and
Spain (1 300 deaths over 2005–09). Most victims were 
males (7–9 in 10), in their late 20s or early 30s, having often 
used cocaine with opioids and sometimes with more drugs. 
Around two-thirds of all reported cases died of an overdose. 
The report also calls for further examination of deaths 
indirectly related to cocaine use.
Available at www.drugsandalcohol.ie/18975
Public expenditure profiles
Cited from Drugnet Europe, No. 80, October–December 
2012
How much do countries in Europe spend on drug-related 
activities as a percentage of their GDP? Do national 
governments allocate specific budgets to drug policy?  
How has national drug-related public expenditure evolved 
over time and what can be expected in the future? These 
are some of the questions which the EMCDDA’s new ‘Public 
expenditure profiles’ aim to answer. Recently published on 
the agency’s website, the profiles cover 30 countries.  
For more, see  
www.emcdda.europa.eu/countries/public-expenditure
Drugnet Europe is the quarterly newsletter of the 
European Monitoring Centre  
for Drugs and Drug Addiction (EMCDDA).  
Drugs in focus is a series of policy briefings published by 
the EMCDDA. Both publications are available at  
www.emcdda.europa.eu.
If you would like a hard copy of the current or 
future issues of either publication, please contact: 
Health Research Board, Knockmaun House,  
42–47 Lower Mount Street, Dublin 2.  
Tel: 01 2345 148; Email: drugnet@hrb.ie
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In brief
On 24 April 2012 the UK Drug Policy Commission 
published Charting new waters: delivering drug policy at 
a time of radical reform and financial austerity. The study 
explores the ability of local areas to achieve the ambitions 
of the UK’s national drugs strategy and the future security of 
investment in drug interventions. The study reveals a broad 
picture of upheaval and uncertainty. www.ukdpc.org.uk 
On 29 June 2012 a British–Irish Council ministerial meeting 
on the misuse of drugs was chaired by the then Minister of 
State Róisín Shortall TD on the island of Jersey. Under the 
heading ‘Young People and Drugs – Breaking the Cycle’, 
issues discussed included evidence of trends in drug use 
among young people, general and targeted prevention 
measures, early intervention and broader treatment issues. 
There was particular focus on the need to support young 
people whose parents are involved in drug use. The 
Ministers also discussed issues around the use and misuse 
of alcohol in their jurisdictions; this arose in the context 
of proposals for the possible expansion of the work of the 
misuse of drugs sectoral group to include alcohol.  
www.britishirishcouncil.org
On 17 July 2012 the Sixth annual report of the independent 
monitoring group for A Vision for Change was published. 
The Independent Monitoring Group (IMG) reports that 
implementation of A Vision for Change (AVFC) has been slow 
and inconsistent. The IMG states that as a matter of urgency, 
specialist mental health services for co-morbid severe mental 
illness and substance abuse problems, inter alia, need to 
be fully developed and delivered. In addition, government 
departments, other than the Department of Health and the 
Department of the Environment, Community and Local 
Government, also need to focus on their responsibilities 
for the implementation of AVFC. According to the IMG, 
there also needs to be a cultural shift in how mental health 
services are delivered, moving from professional dominance 
towards a person-centred, partnership approach, and from a 
largely medicalised and maintenance approach towards one 
based on recovery competencies within the biopsychosocial 
model, as envisaged in AVFC. The IMG notes that the 
principles and practices of a recovery-oriented service appear 
to be developing in localised services and this needs to be 
encouraged and reinforced by a clear national corporate 
policy implementation framework. www.dohc.ie 
On 24 July 2012 the Fifth report of the special rapporteur on 
child protection was laid before the Houses of the Oireachtas. 
In reporting on recent child protection developments in 
the United Kingdom, the special rapporteur, Dr Geoffrey 
Shannon, describes a pilot Family Drug and Alcohol Court 
(FDAC) as ‘a new approach to care proceedings in cases 
where parental substance misuse is a key element in the 
local authority decision to bring proceedings’. Shannon 
reports that the pilot has shown early signs of success and 
recommends that such an initiative should be implemented 
in Ireland. www.dcya.ie 
On 25 July 2012 Harm Reduction International (HRI) 
launched The global state of harm reduction 2012: towards 
an integrated response. First published in 2008, this third 
iteration of the report compiles data on international 
developments since 2010 in HIV prevention among 
people who inject drugs, including needle and syringe 
exchange programmes, opioid substitution therapy and 
drug consumption rooms. The report finds that even in 
countries that have programmes in place to prevent HIV 
via unsafe injecting practices, reach and effectiveness are 
severely undermined in many cases by lack of geographical 
coverage – Ireland is mentioned in this regard. The report 
also explores key issues for developing an integrated 
harm reduction response, such as building effective harm 
reduction services for women who inject drugs, limited 
access to harm reduction services by young people, drug use 
among men who have sex with men, and global progress 
toward drug decriminalisation and sustainability of services 
in challenging environments. To coincide with the launch 
of the report, the new Global State of Harm Reduction 
interactive e-tool has been updated to present the latest 
information on harm reduction policy and programming 
around the world. www.ihra.net 
On 8 September 2012 Thomas Szaz, psychiatrist and 
critic of psychiatry, died aged 92 years. Famous for his 
critique of the concept of ‘mental illness’, arguing that the 
term ‘illness’ can only be applied to a body, not a mind, 
except as a metaphor, Szaz challenged the medicalisation 
of dysfunctional and illegal forms of behaviour, such as the 
consumption of illicit drugs, which, he argued, had led to an 
assumption that individuals, such as drug ‘addicts’, were not 
responsible for their actions. He argued that drug use was 
not an ‘addiction’, to be treated as an illness, but a ‘social 
habit’ to be addressed by the individual as a free agent. 
Among his 36 books were Ceremonial chemistry: the ritual 
persecution of drugs, addicts and pushers (1974) and Our right 
to drugs: the case for a free market (1992).
On 28 September 2012 a Communications paper on 
approaches to promoting and developing an understanding 
of domestic, sexual and gender-based violence was published 
by COSC (The National Office for the Prevention of 
Domestic, Sexual and Gender-based Violence). The paper 
provides suggestions and advice for organisations and 
professionals on developing messages and methods for 
raising awareness, confronting offending behaviour, and 
increasing understanding and recognition of domestic, 
sexual and gender-based violence both in the general 
population and in two population-specific groupings – the 
Traveller community and migrant communities. www.cosc.ie 
On 15 October 2012 A fresh approach to drugs: the final 
report of the UK Drug Policy Commission was published. 
The UKDPC proposes a radical rethink of how responses 
to drug problems are structured. It provides an analysis of 
the evidence for how policies and interventions could be 
improved, with recommendations for policymakers and 
practitioners to address the new and established challenges 
associated with drug use. www.ukdpc.org.uk
On 16 October 2012 Putting people first: action programme 
for effective local government was published. Incorporating 
the final report of the Local Government and Local 
Development Alignment Steering Group,1 the action 
programme states, ‘Local government will be the main 
vehicle of governance and public service at local level – 
leading economic, social and community development, 
delivering efficient and good value services, and representing 
citizens and local communities effectively and accountably.’ 
www.environ.ie 
(Compiled by Brigid Pike)
1. For a description this Steering Group’s interim report,  
see ‘In brief’ in the last issue of Drugnet Ireland  
(No 43, Autumn 2012). 
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Recent publications
Journal articles
The following abstracts are cited from recently published articles relating to the drugs and alcohol situation in Ireland.
Mothers’ experiences of their children’s detoxification in 
the home: results from a pilot study 
Van Hout MC and Bingham T  
Community Practitioner, 2012, 85(7): 30–33  
www.drugsandalcohol.ie/18241
Detoxification from alcohol and/or drugs and the achievement 
of abstinence without formal treatment is often preferred using 
community-based supports from local GPs and family. Family 
members are often involved in the sourcing of information 
on detoxification and treatment options, user advocacy and 
provision of remedial supports while detoxifying within the 
family home. The aim of the research was to describe and 
explore family experiences of self-detoxification processes 
from the perspectives of mothers in the Mid West of Ireland. 
A convenience sample of adult mothers who had experienced 
their child detoxifying in the home (n=9) were interviewed.  
The findings illustrated varied personal definitions of 
detoxification. Addiction stigma and costly experiences 
of treatment and after care pathways facilitated home 
detoxification attempts. A lack of GP advice, support and 
information around safe home detoxification was observed to 
contribute to information and support seeking from friends, 
family and community members with home detoxification 
experience. Self-medication of both licit and illicit substances 
while detoxifying, and relapse cycles were common. The 
research highlights the need for inclusive health and social 
supports provided by GPs, community nurses, RGNs and  
district nurses for families and individuals detoxifying in the 
home setting.
Methadone maintenance and Special Community 
Employment schemes: a study of Irish participants’ views
Van Hout MC and Bingham T  
Journal of Vocational Rehabilitation, 2012, 37(1): 63–73  
www.drugsandalcohol.ie/18303
Specialist vocational training for ex-drug users include 
employment skills training, supported placements and 
therapeutic work programmes. The research was peer led 
by Client Forum representatives of five ‘Special Community 
Employment’ schemes and aimed to explore participant 
experiences of Methadone Stabilization; ‘Special Community 
Employment’ schemes, and Vocational Outcomes. A Client 
Forum consultation (n = 11) and Client Forum representative 
focus groups (n = 2) were used to finalize interview questions. 
In depth interviews with a convenience sample of participants 
from ‘Special Community Employment’ schemes (n = 25) 
were conducted. Content and thematic analysis of narratives 
was undertaken with Client Forum (n = 11) interpretative 
support. The findings are indicative of ‘Special Community 
Employment’ schemes offering methadone maintenance 
participants’ the opportunity to commence recovery, engage 
in vocational training and reintegrate into the community. 
However, participation in these schemes appeared restrictive 
and operated primarily as therapeutic medium, with little 
individual vocational care planning, training or supported work 
placements. Many participants reported leaving these schemes 
unqualified, unemployed and experiencing little aftercare. The 
research underscores the need for extensive revision of ‘Special 
Community Employment’ schemes within an interagency 
approach, so as to provide specific therapeutic supports 
dependent on individual recovery stage, and client specific 
vocational training needs, certification, work placement and 
supportive aftercare.
Substance use and psychiatric disorders in Irish 
adolescents: a cross-sectional study of patients attending 
substance abuse treatment service
James PD, Smyth BP and Apantaku-Olajide T  
Mental Health and Substance Use, 2012, 6 July. Early online.  
www.drugsandalcohol.ie/18305
Little information exists on the levels of psychiatric disorders 
among substance abusing adolescents in Ireland. The aim 
of the study is examine the pattern of psychiatric disorders 
and explore for gender differences among adolescents with 
a substance use disorder (SUD) in Ireland. A cross-sectional 
descriptive study and retrospective review of medical records on 
the 144 most recent admissions at the Youth Drug and Alcohol 
(YoDA) service, Dublin was carried out. Overall, 48% of the 
patients had a lifetime history of psychiatric disorders. Deliberate 
self-harm (DSH) was the most common condition (27.1%), 
followed by attention deficit hyperactivity disorder (20.8%) and 
depression (10.4%). Conduct disorder and oppositional defiant 
disorder were infrequently diagnosed. Compared with boys, the 
girls were more likely to have a lifetime history of psychiatric 
disorders (odds ratio 3.7; p = 0.005). These findings provide 
the first prevalence data on psychiatric disorders in a clinically 
representative sample of Irish adolescents with SUDs. Adolescent 
addiction services should have the skills to assess and manage 
co-occurring mental health problems. There is a need for further 
studies to examine DSH among adolescents with SUDs.
A national study of the retention of Irish opiate users in 
methadone substitution treatment
Mullen L, Barry J, Long J et al.  
American Journal of Drug and Alcohol Abuse, 2012, 2 July.  
Early online.  
www.drugsandalcohol.ie/18304
Background: Retention in treatment is a key indicator of 
methadone treatment success. This study aims to identify factors 
that are associated with retention. Objectives: To determine 
retention in treatment at 12 months for Irish opiate users in 
methadone substitution treatment and to indicate factors 
that increase the likelihood of retention. Methods: National 
cohort study of randomly selected opiate users commencing 
methadone treatment in 1999, 2001, and 2003 (n = 1269). 
Results: Sixty-one per cent of patients remained in continuous 
treatment for more than one year. Retention in treatment at 
12 months was associated with age, gender, facility type, and 
methadone dose. Age and gender were no longer significant 
when adjusted for other variables in the model. Those who 
attended a specialist site were twice as likely to leave methadone 
treatment within 12 months compared with those who attended 
a primary care physician. The most important predictor of 
retention in treatment was methadone dose. Those who 
received <60 mg of methadone were three times more likely to 
leave treatment. Conclusion: Retention in methadone treatment 
is high in Ireland in a variety of settings. The main factors 
influencing retention in methadone treatment was an adequate 
methadone dose and access to a range of treatment settings 
including from primary care physicians. Scientific Significance: 
Providing an adequate dose of methadone during treatment 
will increase the likelihood of treatment retention. Methadone 
treatment by the primary care physician is a successful method 
of retaining opioid users in treatment.
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Retrospective study of outcomes, for patients admitted 
to a Drug Treatment Centre Board 
Somers CJ and O’Connor JJ 
Irish Medical Journal, 2012, 105(9)  
www.drugsandalcohol.ie/18636/
Retrospective study of urinary heroin outcomes of a cohort (123) 
of patients commenced on a methadone treatment program. 
Significantly poorer outcomes were associated with urines 
positive for cocaine (OR 0.69 CI 0.59-0.81) benzodiazepines 
(OR 0.7 CI 0.53-0.93) with prescribing of low dose methadone 
(OR 0.65 CI 0.48-0.87), with urines positive for heroin at time 
of admission (OR 0.74 CI 0.56-0.97) and with behavioural 
sanctions (OR 0.8, CI 0.65-0.98). Improved outcomes were 
associated with granting of take away methadone (OR 1.34 CI 
1.1-1.62). with an indication of improved outcomes associated 
with alcohol positive urines (OR 1.34 CI 0.95-1.9) and increased 
duration of clinic attendance (OR 1.21 CI 0.99-1.47). On 
multiple regression analysis low dose methadone (0.07 CI 0.01-
0.33) prescribing remained negatively associated with urine 
heroin outcomes.
Prognostic factors of 2-year outcomes of patients with 
comorbid bipolar disorder or depression with alcohol 
dependence: importance of early abstinence 
Farren C, Snee L, Daly P and McElroy S  
Alcohol and Alcoholism, 2012, 11 October. Early online.  
www.drugsandalcohol.ie/18576/
Aims: To investigate the prognostic factors that determine 
2-year outcomes in a group of alcohol-dependent patients with 
depression or bipolar disorder who were treated in an intensive 
4-week inpatient programme. 
Methods: This was a longitudinal study of an inpatient 
treatment cohort of dual affective disorder and alcohol-
dependent patients, in Dublin, Ireland. Measurements included 
baseline demographics with follow-up measurements at 
discharge, 3 months, 6 months and 2 years after treatment, 
including alcohol consumption, depression, mania/elation, 
anxiety, craving, drug use and sample blood tests. Factor and 
regression analysis of multiple variables was carried out to 
predict outcomes. 
Results: A total of 189 participants with alcohol dependence 
and comorbid depression (n = 101) or bipolar disorder (n = 
88) were followed over 2 years after discharge from treatment. 
Retention rate was 76% over 2 years. Early abstinence (at 6 
months) predicted better abstinence overall at 2 years; and 
bipolar alcoholics had a better outcome in drinks per drinking 
day than depressed alcoholics at 2 years. Younger participants 
(age 18–30 years) did relatively worse than middle-age (30–50 
years) and older (51 + years) participants in measures of 
abstinence and number of drinks per drinking day at 2 years; 
and females did better than males in number of drinks per 
drinking day at 2 years. 
Conclusion: Dual diagnosis of alcohol dependence and 
depression or bipolar disorder may be treated together with 
intensive intervention and follow-up, and various prognostic 
factors including early abstinence emerge over time that 
influence outcomes over 2 years. 
Best practice promotion in Europe: a web-based tool for 
the dissemination of evidence-based demand reduction 
interventions
Ferri M and Bo A  
Drugs: education, prevention and policy, 2012, 3 December.  
Early online  
www.drugsandalcohol.ie/18927
In 2008, the EMCDDA initiated the creation of a web-based tool 
which bridges scientific evidence and current practice in the 
drug addiction field. The aim is to disseminate evidence-based 
interventions and promote sharing of best practice among 
European countries. The synthesis of the evidence is based on 
sound procedures, implemented according to the methods 
of the Cochrane collaboration (the Drugs and Alcohol Group) 
and the Grade working group. As of October 2012, the portal 
is composed of four modules on the effectiveness of demand 
reduction interventions, a collection of European projects on 
prevention, treatment, harm reduction and social reintegration 
and an inventory of European guidelines and standards. The 
summaries of evidence are user-friendly and provide plain 
language information on the interpretation of the measures 
of effect supporting the evidence, but do not provide specific 
recommendations. The main future challenge of the EMCDDA’s 
best-practice promotion is to enhance the communication of 
evidence to better inform the decision making processes at both 
national and European levels.
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Upcoming events
Compiled by Joan Moore (jmoore@hrb.ie)
January 
31 January 2013
Drugs and alcohol seminar: Managing the performance, 
safety and health risks of employee drug and alcohol use
Venue: Ashling Hotel, Dublin 8  
Organised by / Contact: EAP Institute  
Email: anita@eapinstitute.com  
Tel: +353 51 855733  
www.eapinstitute.com
Information: This seminar will consider the implications for 
business on a proposed new law to test all road users for drug 
driving. Currently commercial drivers who register a reading 
of greater than 20mg/100ml of alcohol are deemed not fit 
to drive and the proposed new drug testing will pose an 
additional threat to employee livelihood. Section 13(1) b of 
the Safety Health and Welfare at Work Act 2005 requires that 
an employee should ensure that he or she is not under the 
influence of an intoxicant to the extent that he or she is in such 
a state as to endanger his or her own safety health or welfare 
at work or that of any other person. Section 19(1) requires that 
employers should assess the risks presented by those hazards 
and include them in a written assessment. A further requirement 
under Section 20(1) of the Act is that the control measures for 
intoxicants should be included in the safety statement.
This seminar will also run on 23 May 2013 at The Prince of 
Wales Hotel, Athlone, Co Westmeath.
February
14 February 2013
Be the Change! DDN Service User Conference 2013
Venue: National Motorcycle Museum, Birmingham, UK  
Organised by / Contact: Drink and Drugs News  
Email: conferences@cjwellings.com  
Tel: 01233 633315
Information: This is your chance to have your say and network 
with colleagues all over the country. Activism, inspiration, 
enterprise and all pathways to recovery will be central to a 
programme that will give every opportunity for service users  
and professionals to share expertise and practical learning.
March
Alcohol Awareness Week planned for March 2013
www.alcoholforum.org
Information: Alcohol Forum, the alcohol-responsibility advocacy 
group based in the North Western area, has announced plans  
to launch the first ever national Alcohol Awareness Week in 
March 2013. The Forum is hoping to organise a national 
conference on 21 March in parallel with the event. Alcohol 
Forum is also a cross-border advocacy group and also offers 
support and advice to families affected by alcohol issues. See 
website for information about the Forum and for further details 
of the conference in due course.
May
6–11 May 2013
Testing the waters: 2013 conference
Venue: Obergurgl, Austria  
Organised by / Contact: European Science Foundation / 
EMCDDA / Innsbruck Leopold-Franzens University  
www.esf.org/index /  
www.emcdda.europa.eu/wastewater-analysis
Information: ‘Testing the waters’ is the title of the first 
international multidisciplinary conference on illicit drugs and 
wastewater. Wastewater analysis is a rapidly developing scientific 
discipline with the potential for monitoring real-time population-
level trends in illicit drug use and for assessing the efficacy of 
drug control interventions. By sampling a source of wastewater – 
for example a sewage influent to a wastewater treatment plant – 
scientists can estimate the total quantity of drugs consumed by 
a community by measuring the levels of illicit drug metabolites 
excreted in urine. The conference will assess the state of the art 
in this emerging scientific
discipline, consolidate research findings and identify a common 
approach and set of methodologies for wastewater analysis 
and monitoring. For information on applications and abstract 
submission, see the ESF website. 
16–17 May 2013
Managing Drug and Alcohol Problems in Primary Care
Venue: National Motorcycle Museum, Birmingham, UK  
Organised by / Contact: Royal College of General Practitioners  
www.rcgp.org.uk/courses-and-events
Information: This, the 18th national conference, will once again 
examine the critical role primary care plays in working with drug 
users, their families and carers. The conference is the largest 
event in the UK for GPs, shared care workers, drug users, nurses 
and other primary care staff, specialists, commissioners and 
researchers interested in, and involved with the management  
of drug users in primary care. 
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